https://me-pedia.org/w/api.php?action=feedcontributions&feedformat=atom&user=Simon+F 2026-04-07T21:43:28Z User contributions MediaWiki 1.43.8 https://me-pedia.org/w/index.php?title=Treatment_trials&diff=243133 2024-08-14T19:04:47Z

<p>Simon F:moved some completed trials from section &quot;ongoing&quot; to section &quot;completed&quot;</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |safety of CBD<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | CBD is safe[https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15988]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidine]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> | -<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | fatigue--[https://www.sciencedirect.com/science/article/pii/S2666354624000115#bib7]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios PR] [https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/ CTA]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> | -<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> | -<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> | -<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-30<br /> |D<br /> |Sulfureous water<br /> |cardiopulmonary, inflammation<br /> |[https://clinicaltrials.gov/study/NCT06294756 NCT06294756]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |Longidaza<br /> |pulmonary<br /> |[https://clinicaltrials.gov/study/NCT06383819 NCT06383819]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-04<br /> |O<br /> |Hi-OxSR Sequential Rebreathing mask <br /> |cognitive<br /> |[https://clinicaltrials.gov/study/NCT06379620 NCT06379620]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |R<br /> |Virtual Reality<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06374446 NCT06374446]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Diaphragmatic breathing<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06330376 NCT06330376]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT06316843 NCT06316843]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |Cognitive training (online)<br /> |cognitive<br /> |[https://clinicaltrials.gov/study/NCT06391489 NCT06391489]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[Modafinil]] &amp; [[Solriamfetol]] &amp; [[Melatonin]] &amp; tailored lighing<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404086 NCT06404086]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |R<br /> |Supervised computerized active program<br /> |cognitive, emotional, functional<br /> |[https://clinicaltrials.gov/study/NCT06315894 NCT06315894]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-10-31<br /> |D<br /> |[[Melatonin]] &amp; lighting<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404112 NCT06404112]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-11-30<br /> |D<br /> |[[Modafinil]] &amp; [[Solriamfetol]]<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404099 NCT06404099]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-15<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |R<br /> |Cardiopulmonary rehabilitation<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06404060 NCT06404060]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-01-31<br /> |R<br /> |[[Pacing]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06404073 NCT06404073]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06267300 NCT06267300]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-30<br /> |D<br /> |[[Pyridostigmine]] &amp; [[Low dose naltrexone]]<br /> |PEM, pain, overall health<br /> |[https://clinicaltrials.gov/study/NCT06366724 NCT06366724]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=243098 2024-08-04T13:44:16Z

<p>Simon F:added result to NAD+ &amp; LDN</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |safety of CBD<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | CBD is safe[https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15988]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidine]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> | -<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | fatigue--[https://www.sciencedirect.com/science/article/pii/S2666354624000115#bib7]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios PR] [https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/ CTA]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> | -<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> | -<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> | -<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-30<br /> |D<br /> |Sulfureous water<br /> |cardiopulmonary, inflammation<br /> |[https://clinicaltrials.gov/study/NCT06294756 NCT06294756]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |Longidaza<br /> |pulmonary<br /> |[https://clinicaltrials.gov/study/NCT06383819 NCT06383819]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-04<br /> |O<br /> |Hi-OxSR Sequential Rebreathing mask <br /> |cognitive<br /> |[https://clinicaltrials.gov/study/NCT06379620 NCT06379620]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |R<br /> |Virtual Reality<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06374446 NCT06374446]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Diaphragmatic breathing<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06330376 NCT06330376]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT06316843 NCT06316843]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |Cognitive training (online)<br /> |cognitive<br /> |[https://clinicaltrials.gov/study/NCT06391489 NCT06391489]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[Modafinil]] &amp; [[Solriamfetol]] &amp; [[Melatonin]] &amp; tailored lighing<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404086 NCT06404086]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |R<br /> |Supervised computerized active program<br /> |cognitive, emotional, functional<br /> |[https://clinicaltrials.gov/study/NCT06315894 NCT06315894]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-10-31<br /> |D<br /> |[[Melatonin]] &amp; lighting<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404112 NCT06404112]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-11-30<br /> |D<br /> |[[Modafinil]] &amp; [[Solriamfetol]]<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404099 NCT06404099]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-15<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |R<br /> |Cardiopulmonary rehabilitation<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06404060 NCT06404060]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-01-31<br /> |R<br /> |[[Pacing]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06404073 NCT06404073]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06267300 NCT06267300]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-30<br /> |D<br /> |[[Pyridostigmine]] &amp; [[Low dose naltrexone]]<br /> |PEM, pain, overall health<br /> |[https://clinicaltrials.gov/study/NCT06366724 NCT06366724]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242792 2024-05-14T17:59:42Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |safety of CBD<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | CBD is safe[https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15988]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidine]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> | -<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios PR] [https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/ CTA]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> | -<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> | -<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> | -<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-30<br /> |D<br /> |Sulfureous water<br /> |cardiopulmonary, inflammation<br /> |[https://clinicaltrials.gov/study/NCT06294756 NCT06294756]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |Longidaza<br /> |pulmonary<br /> |[https://clinicaltrials.gov/study/NCT06383819 NCT06383819]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-04<br /> |O<br /> |Hi-OxSR Sequential Rebreathing mask <br /> |cognitive<br /> |[https://clinicaltrials.gov/study/NCT06379620 NCT06379620]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |R<br /> |Virtual Reality<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06374446 NCT06374446]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Diaphragmatic breathing<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06330376 NCT06330376]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT06316843 NCT06316843]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |Cognitive training (online)<br /> |cognitive<br /> |[https://clinicaltrials.gov/study/NCT06391489 NCT06391489]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[Modafinil]] &amp; [[Solriamfetol]] &amp; [[Melatonin]] &amp; tailored lighing<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404086 NCT06404086]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |R<br /> |Supervised computerized active program<br /> |cognitive, emotional, functional<br /> |[https://clinicaltrials.gov/study/NCT06315894 NCT06315894]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-10-31<br /> |D<br /> |[[Melatonin]] &amp; lighting<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404112 NCT06404112]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-11-30<br /> |D<br /> |[[Modafinil]] &amp; [[Solriamfetol]]<br /> |sleep<br /> |[https://clinicaltrials.gov/study/NCT06404099 NCT06404099]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-15<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |R<br /> |Cardiopulmonary rehabilitation<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06404060 NCT06404060]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-01-31<br /> |R<br /> |[[Pacing]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06404073 NCT06404073]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06267300 NCT06267300]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-30<br /> |D<br /> |[[Pyridostigmine]] &amp; [[Low dose naltrexone]]<br /> |PEM, pain, overall health<br /> |[https://clinicaltrials.gov/study/NCT06366724 NCT06366724]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242791 2024-05-14T14:20:29Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |safety of CBD<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | CBD is safe[https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15988]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidine]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> | -<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios PR] [https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/ CTA]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> | -<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> | -<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> | -<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-30<br /> |D<br /> |Sulfureous water<br /> |cardiopulmonary, inflammation<br /> |[https://clinicaltrials.gov/study/NCT06294756 NCT06294756]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |R<br /> |Virtual Reality<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06374446 NCT06374446]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Diaphragmatic breathing<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06330376 NCT06330376]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT06316843 NCT06316843]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |R<br /> |Supervised computerized active program<br /> |cognitive, emotional, functional<br /> |[https://clinicaltrials.gov/study/NCT06315894 NCT06315894]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-15<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06267300 NCT06267300]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-30<br /> |D<br /> |[[Pyridostigmine]] &amp; [[Low dose naltrexone]]<br /> |PEM, pain, overall health<br /> |[https://clinicaltrials.gov/study/NCT06366724 NCT06366724]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242675 2024-03-29T14:40:44Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |safety of CBD<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | CBD is safe[https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15988]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidine]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> | -<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios PR] [https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/ CTA]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> | -<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> | -<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> | -<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-30<br /> |D<br /> |Sulfureous water<br /> |cardiopulmonary, inflammation<br /> |[https://clinicaltrials.gov/study/NCT06294756 NCT06294756]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Diaphragmatic breathing<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06330376 NCT06330376]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT06316843 NCT06316843]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |R<br /> |Supervised computerized active program<br /> |cognitive, emotional, functional<br /> |[https://clinicaltrials.gov/study/NCT06315894 NCT06315894]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06267300 NCT06267300]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Prevalence_of_myalgic_encephalomyelitis_and_chronic_fatigue_syndrome&diff=242662 2024-03-16T15:40:27Z

<p>Simon F:added reference</p> <hr /> <div>The '''prevalence of myalgic encephalomyelitis and chronic fatigue syndrome''' is estimated at 17-24 million worldwide.&lt;ref&gt;{{Cite web|url=https://ammes.org/how-many-people-have-mecfs/ | title = How Many People Have ME/CFS? – American ME and CFS Society|language=en-US|access-date=2019-01-31}}&lt;/ref&gt;<br /> <br /> According to the National Center for Health Statistics (NCHS) during 2021–2022, 1.3% of adults in the United States had [[ME/CFS]].&lt;ref name=&quot;US&quot;&gt;{{Cite web|url=https://www.cdc.gov/nchs/data/databriefs/db488.pdf|title=Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022|access-date=2024-03-16}}&lt;/ref&gt; This corresponds to about 3.35 million adults or 4.3 million people when extrapolating the number to include minors.<br /> <br /> In 2015, the [[Institute of Medicine report|Institute of Medicine (IOM) Report]] from the [[United States]] National Academy of Sciences estimated there were between 836,000 and 2.5 million patients in the U.S.&lt;ref&gt;{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_ReportBrief.pdf | title = Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining and Illness - Report Brief | last = | first = | author-link =| date = 2015 | website = nataionalacademies.org|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt; A 2018 study based on insurance claims gave &quot;a rough estimate for the number of patients who may be diagnosed with ME or CFS in the U.S.&quot; as between 1.7 million and 3.38 million.&lt;ref name=&quot;:0&quot; /&gt; Via a machine learning model, the same study predicted the prevalence of ME in the U.S. as roughly 2.8 million (857 out of every 100,000 people).&lt;ref name=&quot;:0&quot; /&gt;<br /> <br /> The IOM Report estimated that between 84% and 91% of patients are not diagnosed.&lt;ref&gt;{{Cite web|url=https://www.cdc.gov/me-cfs/about/index.html | title = What is ME/CFS? {{!}} Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | date = 2019-01-18 | website = [[Centers for Disease Control and Prevention]]|language=en-us|access-date=2019-01-31}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_KeyFacts.pdf | title = Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Key Facts | last = | first = | author-link =| date = 2015 | website = nationalacademies.org|publisher=National Academies of Medicine|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt;<br /> <br /> ==Prevalence of ME/CFS==<br /> <br /> {| class=&quot;wikitable sortable&quot;<br /> ! Country<br /> ! Prevalence<br /> ! Population %<br /> ! Year &amp; Reference<br /> |-<br /> | Worldwide || 17,000,000 || ||<br /> |-<br /> | [[Australia]] || 100,000 || ||<br /> |-<br /> | [[Canada]] || 561,000 || 1.9% ||<br /> |-<br /> | [[Germany]] || 300,000 || 0.37% ||<br /> |-<br /> | [[Japan]] || 958,000 || 0.76%||2021&lt;ref name=&quot;KoreaAndJapan&quot;&gt;{{Cite journal|title=Prevalence of Chronic Fatigue Syndrome (CFS) in Korea and Japan: A Meta-Analysis|date=2021-07-21|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347596/|journal=Journal of Clinical Medicine|volume=10|issue=15|pages=3204|last=Lim|first=Eun-Jin|last2=Son|first2=Chang-Gue|doi=10.3390/jcm10153204|pmc=8347596|pmid=34361987|issn=2077-0383}}&lt;/ref&gt;<br /> |-<br /> |[[Korea]]<br /> |399,000<br /> |0.77%<br /> |2021&lt;ref name=&quot;KoreaAndJapan&quot; /&gt;<br /> |-<br /> | [[New Zealand]] || 20,000 || 0.45% ||<br /> |-<br /> | [[Nigeria]] || || 0.68% ||<br /> |-<br /> | England and Wales || 250,000 || 0.4% ||<br /> |-<br /> | [[United States]] || 4,300,000 || 1.3% || 2022&lt;ref name=&quot;US&quot;/&gt;<br /> |}<br /> <br /> ==Notable studies==<br /> *2011, [[chronic fatigue syndrome|CFS]] Prevalence and Risk Factors Over Time&lt;ref&gt;Jason, L. A., Porter, N., Hunnell, J., Rademaker, A., &amp; Richman, J.A. (2011). CFS Prevalence and Risk Factors Over Time. Journal of Health Psychology, 16(3), 445–456. http://doi.org/10.1177/1359105310383603&lt;/ref&gt; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166209/ (Full Text)]<br /> *2015, Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining an Illness&lt;ref name=&quot;:4&quot;&gt;{{Cite web|url=http://iom.nationalacademies.org/~/media/Files/Report%20Files/2015/MECFS/MECFScliniciansguide.pdf | title = Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining an Illness | last = | first = | date = 2015 | website = National Academies|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt; ([http://iom.nationalacademies.org/~/media/Files/Report%20Files/2015/MECFS/MECFScliniciansguide.pdf Full Text])<br /> *2018, Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe-the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review.&lt;ref&gt;{{Cite journal | last = Murovska | first = Modra | last2 = Lacerda | first2 = Eliana | last3 = Sekulic | first3 = Slobodan | last4 = Capelli | first4 = Enrica | last5 = Lorusso | first5 = Lorenzo | last6 = Shikova | first6 = Evelina | last7 = Scheibenbogen | first7 = Carmen | last8 = Alegre | first8 = Jose | last9 = Pheby | first9 = Derek | date = 2018-09-01 | title = Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review | url =https://bmjopen.bmj.com/content/8/9/e020817|journal=BMJ Open|language=en|volume=8|issue=9| pages = e020817|doi=10.1136/bmjopen-2017-020817|issn=2044-6055|pmid=30181183}}&lt;/ref&gt; ([https://bmjopen.bmj.com/content/8/9/e020817.full Full text])<br /> *2018, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning&lt;ref name=&quot;:0&quot;&gt;{{Cite journal | last = Valdez | first = Ashley R. | author-link = Ashley Valdez | last2 = Hancock | first2 = Elizabeth E. | authorlink2 = Elizabeth Hancock | last3 = Adebayo | first3 = Seyi | authorlink3 = Seyi Adebayo | last4 = Kiernicki | first4 = David J. | authorlink4 = David Kiernicki | last5 = Proskauer | first5 = Daniel | authorlink5 = Daniel Proskauer | last6 = Attewell | first6 = John R. | authorlink6 = John Attewell | last7 = Bateman | first7 = Lucinda | authorlink7 = Lucinda Bateman | last8 = DeMaria | first8 = Alfred | authorlink8 = Alfred DeMaria | last9 = Lapp | first9 = Charles W. | authorlink9 = Charles Lapp | last10 = Rowe | first10 = Peter C. | authorlink10 = Peter Rowe | last11 = Proskauer | first11 = Charmian | authorlink11 = Charmaine Proskauer | date = 2019-01-08 | title = Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning | url =https://www.frontiersin.org/article/10.3389/fped.2018.00412/full|journal=Frontiers in Pediatrics|volume=6|issue=|pages=|doi=10.3389/fped.2018.00412|issn=2296-2360|quote=|via=}}&lt;/ref&gt; ([https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331450/ Full text])<br /> *2020, Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)&lt;ref name=&quot;pmid32093722&quot;&gt;{{cite journal |vauthors=Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG |title=Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) |journal=Journal of Translational Medicine |volume=18 |issue=1 |pages=100 |date=February 2020 |pmid=32093722 |pmc=7038594 |doi=10.1186/s12967-020-02269-0 |url=}}&lt;/ref&gt;<br /> <br /> == See also ==<br /> * [[Epidemiology of myalgic encephalomyelitis and chronic fatigue syndrome|Epidemiology]]<br /> * [[Onset of ME/CFS|Onset]]<br /> * [[Pediatric myalgic encephalomyelitis and chronic fatigue syndrome|Pediatric]]<br /> * [[Prognosis for myalgic encephalomyelitis and chronic fatigue syndrome|Prognosis]]<br /> * [[Eightfold increase in ME/CFS incidence in the 1980s]]<br /> <br /> == References ==<br /> {{Reflist}}<br /> <br /> [[Category:Core topics]]</div>

Simon F https://me-pedia.org/w/index.php?title=Prevalence_of_myalgic_encephalomyelitis_and_chronic_fatigue_syndrome&diff=242661 2024-03-16T15:38:58Z

<p>Simon F:/* Prevalence of ME/CFS */ added citation</p> <hr /> <div>The '''prevalence of myalgic encephalomyelitis and chronic fatigue syndrome''' is estimated at 17-24 million worldwide.&lt;ref&gt;{{Cite web|url=https://ammes.org/how-many-people-have-mecfs/ | title = How Many People Have ME/CFS? – American ME and CFS Society|language=en-US|access-date=2019-01-31}}&lt;/ref&gt;<br /> <br /> According to the National Center for Health Statistics (NCHS) during 2021–2022, 1.3% of adults in the United States had [[ME/CFS]].&lt;ref&gt;{{Cite web|url=https://www.cdc.gov/nchs/data/databriefs/db488.pdf|title=Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022|access-date=2024-03-16}}&lt;/ref&gt; This corresponds to about 3.35 million adults or 4.3 million people when extrapolating the number to include minors.<br /> <br /> In 2015, the [[Institute of Medicine report|Institute of Medicine (IOM) Report]] from the [[United States]] National Academy of Sciences estimated there were between 836,000 and 2.5 million patients in the U.S.&lt;ref&gt;{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_ReportBrief.pdf | title = Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining and Illness - Report Brief | last = | first = | author-link =| date = 2015 | website = nataionalacademies.org|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt; A 2018 study based on insurance claims gave &quot;a rough estimate for the number of patients who may be diagnosed with ME or CFS in the U.S.&quot; as between 1.7 million and 3.38 million.&lt;ref name=&quot;:0&quot; /&gt; Via a machine learning model, the same study predicted the prevalence of ME in the U.S. as roughly 2.8 million (857 out of every 100,000 people).&lt;ref name=&quot;:0&quot; /&gt;<br /> <br /> The IOM Report estimated that between 84% and 91% of patients are not diagnosed.&lt;ref&gt;{{Cite web|url=https://www.cdc.gov/me-cfs/about/index.html | title = What is ME/CFS? {{!}} Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | date = 2019-01-18 | website = [[Centers for Disease Control and Prevention]]|language=en-us|access-date=2019-01-31}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_KeyFacts.pdf | title = Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Key Facts | last = | first = | author-link =| date = 2015 | website = nationalacademies.org|publisher=National Academies of Medicine|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt;<br /> <br /> ==Prevalence of ME/CFS==<br /> <br /> {| class=&quot;wikitable sortable&quot;<br /> ! Country<br /> ! Prevalence<br /> ! Population %<br /> ! Year &amp; Reference<br /> |-<br /> | Worldwide || 17,000,000 || ||<br /> |-<br /> | [[Australia]] || 100,000 || ||<br /> |-<br /> | [[Canada]] || 561,000 || 1.9% ||<br /> |-<br /> | [[Germany]] || 300,000 || 0.37% ||<br /> |-<br /> | [[Japan]] || 958,000 || 0.76%||2021&lt;ref name=&quot;KoreaAndJapan&quot;&gt;{{Cite journal|title=Prevalence of Chronic Fatigue Syndrome (CFS) in Korea and Japan: A Meta-Analysis|date=2021-07-21|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347596/|journal=Journal of Clinical Medicine|volume=10|issue=15|pages=3204|last=Lim|first=Eun-Jin|last2=Son|first2=Chang-Gue|doi=10.3390/jcm10153204|pmc=8347596|pmid=34361987|issn=2077-0383}}&lt;/ref&gt;<br /> |-<br /> |[[Korea]]<br /> |399,000<br /> |0.77%<br /> |2021&lt;ref name=&quot;KoreaAndJapan&quot; /&gt;<br /> |-<br /> | [[New Zealand]] || 20,000 || 0.45% ||<br /> |-<br /> | [[Nigeria]] || || 0.68% ||<br /> |-<br /> | England and Wales || 250,000 || 0.4% ||<br /> |-<br /> | [[United States]] || 4,300,000 || 1.3% || 2022<br /> |}<br /> <br /> ==Notable studies==<br /> *2011, [[chronic fatigue syndrome|CFS]] Prevalence and Risk Factors Over Time&lt;ref&gt;Jason, L. A., Porter, N., Hunnell, J., Rademaker, A., &amp; Richman, J.A. (2011). CFS Prevalence and Risk Factors Over Time. Journal of Health Psychology, 16(3), 445–456. http://doi.org/10.1177/1359105310383603&lt;/ref&gt; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166209/ (Full Text)]<br /> *2015, Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining an Illness&lt;ref name=&quot;:4&quot;&gt;{{Cite web|url=http://iom.nationalacademies.org/~/media/Files/Report%20Files/2015/MECFS/MECFScliniciansguide.pdf | title = Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining an Illness | last = | first = | date = 2015 | website = National Academies|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt; ([http://iom.nationalacademies.org/~/media/Files/Report%20Files/2015/MECFS/MECFScliniciansguide.pdf Full Text])<br /> *2018, Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe-the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review.&lt;ref&gt;{{Cite journal | last = Murovska | first = Modra | last2 = Lacerda | first2 = Eliana | last3 = Sekulic | first3 = Slobodan | last4 = Capelli | first4 = Enrica | last5 = Lorusso | first5 = Lorenzo | last6 = Shikova | first6 = Evelina | last7 = Scheibenbogen | first7 = Carmen | last8 = Alegre | first8 = Jose | last9 = Pheby | first9 = Derek | date = 2018-09-01 | title = Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review | url =https://bmjopen.bmj.com/content/8/9/e020817|journal=BMJ Open|language=en|volume=8|issue=9| pages = e020817|doi=10.1136/bmjopen-2017-020817|issn=2044-6055|pmid=30181183}}&lt;/ref&gt; ([https://bmjopen.bmj.com/content/8/9/e020817.full Full text])<br /> *2018, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning&lt;ref name=&quot;:0&quot;&gt;{{Cite journal | last = Valdez | first = Ashley R. | author-link = Ashley Valdez | last2 = Hancock | first2 = Elizabeth E. | authorlink2 = Elizabeth Hancock | last3 = Adebayo | first3 = Seyi | authorlink3 = Seyi Adebayo | last4 = Kiernicki | first4 = David J. | authorlink4 = David Kiernicki | last5 = Proskauer | first5 = Daniel | authorlink5 = Daniel Proskauer | last6 = Attewell | first6 = John R. | authorlink6 = John Attewell | last7 = Bateman | first7 = Lucinda | authorlink7 = Lucinda Bateman | last8 = DeMaria | first8 = Alfred | authorlink8 = Alfred DeMaria | last9 = Lapp | first9 = Charles W. | authorlink9 = Charles Lapp | last10 = Rowe | first10 = Peter C. | authorlink10 = Peter Rowe | last11 = Proskauer | first11 = Charmian | authorlink11 = Charmaine Proskauer | date = 2019-01-08 | title = Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning | url =https://www.frontiersin.org/article/10.3389/fped.2018.00412/full|journal=Frontiers in Pediatrics|volume=6|issue=|pages=|doi=10.3389/fped.2018.00412|issn=2296-2360|quote=|via=}}&lt;/ref&gt; ([https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331450/ Full text])<br /> *2020, Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)&lt;ref name=&quot;pmid32093722&quot;&gt;{{cite journal |vauthors=Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG |title=Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) |journal=Journal of Translational Medicine |volume=18 |issue=1 |pages=100 |date=February 2020 |pmid=32093722 |pmc=7038594 |doi=10.1186/s12967-020-02269-0 |url=}}&lt;/ref&gt;<br /> <br /> == See also ==<br /> * [[Epidemiology of myalgic encephalomyelitis and chronic fatigue syndrome|Epidemiology]]<br /> * [[Onset of ME/CFS|Onset]]<br /> * [[Pediatric myalgic encephalomyelitis and chronic fatigue syndrome|Pediatric]]<br /> * [[Prognosis for myalgic encephalomyelitis and chronic fatigue syndrome|Prognosis]]<br /> * [[Eightfold increase in ME/CFS incidence in the 1980s]]<br /> <br /> == References ==<br /> {{Reflist}}<br /> <br /> [[Category:Core topics]]</div>

Simon F https://me-pedia.org/w/index.php?title=Prevalence_of_myalgic_encephalomyelitis_and_chronic_fatigue_syndrome&diff=242660 2024-03-16T15:32:04Z

<p>Simon F:/* Prevalence of ME/CFS */ Updated numbers</p> <hr /> <div>The '''prevalence of myalgic encephalomyelitis and chronic fatigue syndrome''' is estimated at 17-24 million worldwide.&lt;ref&gt;{{Cite web|url=https://ammes.org/how-many-people-have-mecfs/ | title = How Many People Have ME/CFS? – American ME and CFS Society|language=en-US|access-date=2019-01-31}}&lt;/ref&gt;<br /> <br /> According to the National Center for Health Statistics (NCHS) during 2021–2022, 1.3% of adults in the United States had [[ME/CFS]].&lt;ref&gt;{{Cite web|url=https://www.cdc.gov/nchs/data/databriefs/db488.pdf|title=Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in Adults: United States, 2021–2022|access-date=2024-03-16}}&lt;/ref&gt; This corresponds to about 3.35 million adults or 4.3 million people when extrapolating the number to include minors.<br /> <br /> In 2015, the [[Institute of Medicine report|Institute of Medicine (IOM) Report]] from the [[United States]] National Academy of Sciences estimated there were between 836,000 and 2.5 million patients in the U.S.&lt;ref&gt;{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_ReportBrief.pdf | title = Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining and Illness - Report Brief | last = | first = | author-link =| date = 2015 | website = nataionalacademies.org|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt; A 2018 study based on insurance claims gave &quot;a rough estimate for the number of patients who may be diagnosed with ME or CFS in the U.S.&quot; as between 1.7 million and 3.38 million.&lt;ref name=&quot;:0&quot; /&gt; Via a machine learning model, the same study predicted the prevalence of ME in the U.S. as roughly 2.8 million (857 out of every 100,000 people).&lt;ref name=&quot;:0&quot; /&gt;<br /> <br /> The IOM Report estimated that between 84% and 91% of patients are not diagnosed.&lt;ref&gt;{{Cite web|url=https://www.cdc.gov/me-cfs/about/index.html | title = What is ME/CFS? {{!}} Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | date = 2019-01-18 | website = [[Centers for Disease Control and Prevention]]|language=en-us|access-date=2019-01-31}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|url=https://www.nap.edu/resource/19012/MECFS_KeyFacts.pdf | title = Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Key Facts | last = | first = | author-link =| date = 2015 | website = nationalacademies.org|publisher=National Academies of Medicine|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt;<br /> <br /> ==Prevalence of ME/CFS==<br /> <br /> {| class=&quot;wikitable sortable&quot;<br /> ! Country<br /> ! Prevalence<br /> ! Population %<br /> ! Year of estimate<br /> |-<br /> | Worldwide || 17,000,000 || ||<br /> |-<br /> | [[Australia]] || 100,000 || ||<br /> |-<br /> | [[Canada]] || 561,000 || 1.9% ||<br /> |-<br /> | [[Germany]] || 300,000 || 0.37% ||<br /> |-<br /> | [[Japan]] || 958,000 || 0.76%&lt;ref&gt;{{Cite journal|title=Prevalence of Chronic Fatigue Syndrome (CFS) in Korea and Japan: A Meta-Analysis|date=2021-07-21|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8347596/|journal=Journal of Clinical Medicine|volume=10|issue=15|pages=3204|last=Lim|first=Eun-Jin|last2=Son|first2=Chang-Gue|doi=10.3390/jcm10153204|pmc=8347596|pmid=34361987|issn=2077-0383}}&lt;/ref&gt;||2021<br /> |-<br /> |[[Korea]]<br /> |399,000<br /> |0.77%<br /> |2021<br /> |-<br /> | [[New Zealand]] || 20,000 || 0.45% ||<br /> |-<br /> | [[Nigeria]] || || 0.68% ||<br /> |-<br /> | England and Wales || 250,000 || 0.4% ||<br /> |-<br /> | [[United States]] || 4,300,000 || 1.3% || 2022<br /> |}<br /> <br /> ==Notable studies==<br /> *2011, [[chronic fatigue syndrome|CFS]] Prevalence and Risk Factors Over Time&lt;ref&gt;Jason, L. A., Porter, N., Hunnell, J., Rademaker, A., &amp; Richman, J.A. (2011). CFS Prevalence and Risk Factors Over Time. Journal of Health Psychology, 16(3), 445–456. http://doi.org/10.1177/1359105310383603&lt;/ref&gt; [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3166209/ (Full Text)]<br /> *2015, Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining an Illness&lt;ref name=&quot;:4&quot;&gt;{{Cite web|url=http://iom.nationalacademies.org/~/media/Files/Report%20Files/2015/MECFS/MECFScliniciansguide.pdf | title = Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome - Redefining an Illness | last = | first = | date = 2015 | website = National Academies|archive-url=|archive-date=|url-status=|access-date=}}&lt;/ref&gt; ([http://iom.nationalacademies.org/~/media/Files/Report%20Files/2015/MECFS/MECFScliniciansguide.pdf Full Text])<br /> *2018, Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe-the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review.&lt;ref&gt;{{Cite journal | last = Murovska | first = Modra | last2 = Lacerda | first2 = Eliana | last3 = Sekulic | first3 = Slobodan | last4 = Capelli | first4 = Enrica | last5 = Lorusso | first5 = Lorenzo | last6 = Shikova | first6 = Evelina | last7 = Scheibenbogen | first7 = Carmen | last8 = Alegre | first8 = Jose | last9 = Pheby | first9 = Derek | date = 2018-09-01 | title = Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe—the Euro-epiME study from the European network EUROMENE: a protocol for a systematic review | url =https://bmjopen.bmj.com/content/8/9/e020817|journal=BMJ Open|language=en|volume=8|issue=9| pages = e020817|doi=10.1136/bmjopen-2017-020817|issn=2044-6055|pmid=30181183}}&lt;/ref&gt; ([https://bmjopen.bmj.com/content/8/9/e020817.full Full text])<br /> *2018, Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning&lt;ref name=&quot;:0&quot;&gt;{{Cite journal | last = Valdez | first = Ashley R. | author-link = Ashley Valdez | last2 = Hancock | first2 = Elizabeth E. | authorlink2 = Elizabeth Hancock | last3 = Adebayo | first3 = Seyi | authorlink3 = Seyi Adebayo | last4 = Kiernicki | first4 = David J. | authorlink4 = David Kiernicki | last5 = Proskauer | first5 = Daniel | authorlink5 = Daniel Proskauer | last6 = Attewell | first6 = John R. | authorlink6 = John Attewell | last7 = Bateman | first7 = Lucinda | authorlink7 = Lucinda Bateman | last8 = DeMaria | first8 = Alfred | authorlink8 = Alfred DeMaria | last9 = Lapp | first9 = Charles W. | authorlink9 = Charles Lapp | last10 = Rowe | first10 = Peter C. | authorlink10 = Peter Rowe | last11 = Proskauer | first11 = Charmian | authorlink11 = Charmaine Proskauer | date = 2019-01-08 | title = Estimating Prevalence, Demographics, and Costs of ME/CFS Using Large Scale Medical Claims Data and Machine Learning | url =https://www.frontiersin.org/article/10.3389/fped.2018.00412/full|journal=Frontiers in Pediatrics|volume=6|issue=|pages=|doi=10.3389/fped.2018.00412|issn=2296-2360|quote=|via=}}&lt;/ref&gt; ([https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6331450/ Full text])<br /> *2020, Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME)&lt;ref name=&quot;pmid32093722&quot;&gt;{{cite journal |vauthors=Lim EJ, Ahn YC, Jang ES, Lee SW, Lee SH, Son CG |title=Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) |journal=Journal of Translational Medicine |volume=18 |issue=1 |pages=100 |date=February 2020 |pmid=32093722 |pmc=7038594 |doi=10.1186/s12967-020-02269-0 |url=}}&lt;/ref&gt;<br /> <br /> == See also ==<br /> * [[Epidemiology of myalgic encephalomyelitis and chronic fatigue syndrome|Epidemiology]]<br /> * [[Onset of ME/CFS|Onset]]<br /> * [[Pediatric myalgic encephalomyelitis and chronic fatigue syndrome|Pediatric]]<br /> * [[Prognosis for myalgic encephalomyelitis and chronic fatigue syndrome|Prognosis]]<br /> * [[Eightfold increase in ME/CFS incidence in the 1980s]]<br /> <br /> == References ==<br /> {{Reflist}}<br /> <br /> [[Category:Core topics]]</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242627 2024-02-25T18:02:00Z

<p>Simon F:/* Completed trials */ checked for publications</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |safety of CBD<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | CBD is safe[https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bcp.15988]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidine]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> | -<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios PR] [https://www.clinicaltrialsarena.com/news/virios-long-covid-antiviral/ CTA]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> | -<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> | -<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> | -<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06267300 NCT06267300]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242625 2024-02-23T19:43:59Z

<p>Simon F:addedn 1 line</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06267300 NCT06267300]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=MEpedia_talk:Contents&diff=242602 2024-02-16T16:15:55Z

<p>Simon F:/* Request for simple updates */ Added request for new link</p> <hr /> <div>==Request for simple updates ==<br /> <br /> ===Link to new page: Treatment trials===<br /> <br /> I created a new page containing a long list of clinical trials aiming at testing potential treatments for ME/CFS &amp; PASC. It's this page here: [[Treatment trials]]<br /> It was tremendous effort and it's still work in progress. But at the time of writing this it contains all relevant clinical trials published on clinicaltrials.gov with an estimated completion date after 2021. This list gives me hope that one day there will be an end to my suffering - and hopefully I it can give hope to others, too.<br /> It would possibly make sense to link it in the &quot;Potential treatments&quot; or in the &quot;Research&quot; section.<br /> What do you think?<br /> <br /> ==Completed edits==<br /> {{collapse top}}<br /> ===Double redirects ===<br /> [[User:Kmdenmark]] Can the links going to double redirects be fixed, these are typically links to pages with capitals in their names, e.g. Myalgic Encephalomyelitis should link to &lt;nowiki&gt; [[myalgic encephalomyelitis |Myalgic Encephalomyelitis]] &lt;/nowiki&gt; and the same for chronic fatigue syndrome too. There might be quite a few others. Thank you ~[[User:Notjusttired|Njt]] ([[User talk:Notjusttired|talk]]) 19:15, November 15, 2021 (UTC)<br /> :These have been done ~[[User:Notjusttired|Njt]] ([[User talk:Notjusttired|talk]]) 22:06, April 18, 2022 (UTC)<br /> <br /> ===Disease Names &amp; Definitions===<br /> [[User:Kmdenmark]] Can you please check this code so it links to the category rather than a redirect. Thanks [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:55, July 22, 2019 (EDT)<br /> &lt;pre &gt;<br /> <br /> ==Disease Names &amp; Definitions==<br /> <br /> {{PagesInCategory|Disease Names &amp; Definitions|mode=unordered|columnCount=3}}<br /> <br /> &lt;/pre &gt;<br /> New code:<br /> &lt;pre &gt;<br /> <br /> ==Disease Names &amp; Definitions==<br /> <br /> {{PagesInCategory|Disease names and definitions|mode=unordered|columnCount=3}}<br /> <br /> &lt;/pre &gt;<br /> <br /> ::Done! [[User:Kmdenmark|Kmdenmark]] ([[User talk:Kmdenmark|talk]]) 15:10, July 24, 2019 (EDT)<br /> <br /> ==Open letters ==<br /> Please add this under the Open letters heading, at the very bottom of the page:<br /> &lt;nowiki&gt;<br /> {{PagesInCategory|Open letters|mode=inline}} <br /> &lt;/nowiki &gt;<br /> (but without the 'nowiki' bits. This should then list the open letters. [[User:Kmdenmark]] [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 23:04, 2 May 2019 (EDT)<br /> :Done! [[User:Kmdenmark|Kmdenmark]] ([[User talk:Kmdenmark|talk]]) 15:56, 11 May 2019 (EDT)<br /> :: {{Thanks}} [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:55, July 22, 2019 (EDT)<br /> <br /> ==Edits done ==<br /> * Remove the comma and space before the Nutrients heading <br /> * Treatments: Add Pain relief (analgesics)<br /> [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 14:01, 5 November 2018 (EST)<br /> [[User:Kmdenmark]] can you do this? [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:09, 29 April 2019 (EDT)<br /> ::Edits done [[User:Kmdenmark|Kmdenmark]] ([[User talk:Kmdenmark|talk]]) 18:46, 2 May 2019 (EDT)<br /> :::Thanks [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 23:04, 2 May 2019 (EDT)<br /> <br /> == How should the main page be organized? ==<br /> <br /> I worry that if we add bullets to all the sections, the page will become impossibly long (I have a hard time with page scrolling...). I like the compactness of having links in paragraph form but understand it makes it hard to read. Wonder if there is a compromise? --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 05:51, 27 November 2015 (PST)<br /> <br /> : My vote would be to use wiki categories to organize everything. [[User:Analogue|Analogue]] ([[User talk:Analogue|talk]]) 00:36, 28 November 2015 (PST)<br /> <br /> :: I agree that would be good in the long run – I think for now the purpose of the main page is just to give folks a sense of which articles they can contribute to, because 99% of the content someone might search for isn't actually here yet – of course there is so much more now that the front page may be becoming a little overwhelming and should probably be pared down. Would the idea then be to link to the category pages from the main page? If we create categories, we should probably have a discussion about what are the right categories ::--[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:41, 28 November 2015 (PST)<br /> <br /> ::: Yes that's what I was thinking, front page could list/link to the categories. You've already essentially been organizing it in categories already. [[User:Analogue|Analogue]] ([[User talk:Analogue|talk]]) 15:17, 28 November 2015 (PST)<br /> <br /> Maybe we can start a discussion here about categories? Ollie and others might be more likely to see it over here: http://my.meaction.net/local_chapters/mepedia --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:43, 28 November 2015 (PST) Actually – I will start a discussion and direct folks to this talk page.<br /> <br /> With these decisions I think we should bear in mind it's less a case of &quot;Should we do X?&quot; but the question is &quot;Should we do X or Y FIRST?&quot;. In terms of priority I think covering the key content areas and filling out stub pages is more important so the wiki becomes genuinely useful as soon as possible. I like the current home page as it's easy to see what needs doing and shows what the wiki is for, but I completely agree it will ultimately change in future and categories are likely to work well as they allow us to specify where a page goes IN that page, rather than elsewhere. In the meantime I would prefer comma-separated lists rather than bullets so the page is not unnecessarily long. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 01:56, 29 November 2015 (PST)<br /> <br /> Can I suggest that if we keep the current format (at least for now) that we add commas between items so we have &quot;Item 1, Item 2, Item 3&quot; rather than &quot;Item 1 Item 2 Item 3&quot; as it will be much clearer. At the same time we can also reorder the items alphabetically. Later we could use each section as the basis for a category. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 02:25, 29 November 2015 (PST)<br /> <br /> I agree with commas or a period. Blogs: Blog 1.Blog 2.Blog 3.Blog 4 The black will stand out against the red or blue. Also, I agree while being populated keeping it the way it is with commas or periods added will work or just leave alone if no one is up to putting them in. I guess in future it would make sense that '''each heading''' that now exists becomes '''a page''' and each of these pages is listed on the '''MAIN PAGE'''.--[[User:DxCFS|DxCFS]] ([[User talk:DxCFS|talk]]) 15:39, 29 November 2015 (PST)<br /> <br /> This all sounds great! The page as it stands now isn't at all a problem for me but everyone is different in terms of their capacities and just want to make sure the current layout isn't a barrier to others participating. I do think as we build out new pages, it would be wise, though, to keep categories in mind as it will save time. I wonder if categories are mutually exclusive or if a single article can be tagged with multiple categories? --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 16:50, 30 November 2015 (PST)<br /> <br /> I've reformatted the very first section (infectious agents) so the items are in alphabetical order, and comma separated. I see this as a temporary solution - the more I think about it the more I am inclined to agree we should use categories for these things as the category is specified within the specific page, and category lists are created automatically. But at least for now the commas and ordering help readability. Let me know if you think it looks like an improvements, and I can reformat the rest. Where names are like &quot;The Lancet&quot; we can alphabetise based on the first proper word, eg Lancet. Generally I think we should alphabetise based on the page title (eg Jonathan Edwards goes under J) to keep things simple. Perhaps once we have created the vast majority of the stub pages, we can look to reformat. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 04:28, 5 December 2015 (PST)<br /> <br /> Hi Olliec,<br /> <br /> I think the comma will work even though I can barely see it it seems to at least put 2 spaces between each item and the alphabetizing will probably help a lot. Right now we see a GIANT main page and I think the main page should eventually be just the main heading without the items under them and then you access that header which is its own page. Then the items for just that header will come up which I think will lend itself to better navigation and just easier on they eyes whether items remain as they are or the category option is used.<br /> <br /> Nothing like the blue link eye burn that is much like what you get with Reddit. Plus scrolling is a pain for initial navigation for a lot of patients. But if this is not in the near future then yes, start plugging in commas and alphabetizing and I hope someone else can help you out because right now I just can't. --[[User:DxCFS|DxCFS]] ([[User talk:DxCFS|talk]]) 08:35, 7 December 2015 (PST)<br /> <br /> please can we make the capitalisation consistent for the links/pages ? it's much easier to do this now, than fix it afterwards.--[[User:Suelala|Suelala]] ([[User talk:Suelala|talk]]) 21:56, 7 December 2015 (PST)<br /> <br /> I agree we must fix the capitalization. We're already seeing broken links as there is a mismatch. I figure best to copy Wikipedia which seems to say that title capitalise the first letter ONLY, unless it's a proper name. ie we have titles like these: &quot;Cognitive behavioral therapy&quot;, &quot;Post-exertional malaise&quot;, &quot;Royal Free Hospital&quot;, &quot;Nancy Klimas&quot;. No link should start with a lower-case letter (I think it's impossible for a page to actually have a lower case start letter). I've added this to the guidelines. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 01:08, 9 December 2015 (PST)<br /> <br /> Reading everything above it looks like adding commas into some of the topic lists in the last section will help. I am happy to go in and clean this up by doing that.<br /> <br /> == Using Categories ==<br /> <br /> Here are some examples of existing category pages (i think these are the only ones):<br /> <br /> http://www.me-pedia.org/index.php?title=Category:Diagnoses<br /> http://www.me-pedia.org/index.php?title=Category:Definitions<br /> http://www.me-pedia.org/index.php?title=Category:Medical_hypotheses<br /> <br /> Categories can also have hierarchies: https://www.mediawiki.org/wiki/Help:Categories<br /> <br /> I actually like having a listing of nearly every article *somewhere* as it helps me to monitor where we are in this early stage. So perhaps we keep what we have but put a section higher up with top level categories so folks can use that for browsing and scroll down only if they want to? --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:49, 28 November 2015 (PST)<br /> : This link shows ALL articles: http://me-pedia.org/index.php?title=Special%3AAllPages&amp;from=&amp;to=&amp;namespace=0&amp;hideredirects=1 [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 00:58, 10 December 2015 (PST)<br /> <br /> There are also some great category extensions: https://www.mediawiki.org/wiki/Category:Category_extensions --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:59, 28 November 2015 (PST)<br /> <br /> {{collapse bottom}}<br /> <br /> ==Page layout and contents ==<br /> <br /> ===Category extension code for &quot;By country&quot;===<br /> Can you remove numbers? Put bullets or nothing. Also, can we put Categories of Africa, Asia, Australia &amp; New Zealand in a line instead of stacked; one after the other. There must be a code that can line them up! I really, really hate the category extensions and even if you use them you don't have to organize the front page using them. I think it makes things messier. I really don't think I can express enough how the front page cannot have all this crap on it. Better to have a subheading, click on the subheading and you get what you want. --[[User:DxCFS|DxCFS]] ([[User talk:DxCFS|talk]]) 20:12, 24 April 2016 (PDT)<br /> <br /> === How can we make the contents more presentable? ===<br /> <br /> This Contents page is embarrassingly unsightly, at least for the general public.<br /> &lt;br&gt;Is there some way that we can make it more presentable to the general public?<br /> &lt;br&gt;(I love the use of categories, maybe there is some way to hide/show individual categories?)<br /> &lt;br&gt;[[User:Pyrrhus|Pyrrhus]] ([[User talk:Pyrrhus|talk]]) 22:40, 26 February 2019 (EST)<br /> :Portals might be the way to do this. Check the new ''List of Portals'' and ''MEpedia portals'' in progress - linked to the top and bottom of the Main page, and to each individual portal eg [[Portal:Digestive system]]. These are suggested links from the portal skeleton eg Browsebar template, I'm currently working on them based on example layout on Wikipedia, and a list of categories is part of that. An overall category page would also be helpful. [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:15, 29 April 2019 (EDT)<br /> <br /> ===How is this page to be maintained? ===<br /> <br /> With the ongoing changes to our Categories and sub-Categories, how can we ensure that this page is up-to-date?<br /> &lt;br&gt;Do we need to categorize the remaining static links on this page?<br /> &lt;br&gt;[[User:Pyrrhus|Pyrrhus]] ([[User talk:Pyrrhus|talk]]) 18:43, 5 March 2019 (EST)</div>

Simon F https://me-pedia.org/w/index.php?title=MEpedia_talk:Contents&diff=242601 2024-02-16T16:06:41Z

<p>Simon F:/* Competed edits */ Typo in the title</p> <hr /> <div>==Request for simple updates ==<br /> <br /> ==Completed edits==<br /> {{collapse top}}<br /> ===Double redirects ===<br /> [[User:Kmdenmark]] Can the links going to double redirects be fixed, these are typically links to pages with capitals in their names, e.g. Myalgic Encephalomyelitis should link to &lt;nowiki&gt; [[myalgic encephalomyelitis |Myalgic Encephalomyelitis]] &lt;/nowiki&gt; and the same for chronic fatigue syndrome too. There might be quite a few others. Thank you ~[[User:Notjusttired|Njt]] ([[User talk:Notjusttired|talk]]) 19:15, November 15, 2021 (UTC)<br /> :These have been done ~[[User:Notjusttired|Njt]] ([[User talk:Notjusttired|talk]]) 22:06, April 18, 2022 (UTC)<br /> <br /> ===Disease Names &amp; Definitions===<br /> [[User:Kmdenmark]] Can you please check this code so it links to the category rather than a redirect. Thanks [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:55, July 22, 2019 (EDT)<br /> &lt;pre &gt;<br /> <br /> ==Disease Names &amp; Definitions==<br /> <br /> {{PagesInCategory|Disease Names &amp; Definitions|mode=unordered|columnCount=3}}<br /> <br /> &lt;/pre &gt;<br /> New code:<br /> &lt;pre &gt;<br /> <br /> ==Disease Names &amp; Definitions==<br /> <br /> {{PagesInCategory|Disease names and definitions|mode=unordered|columnCount=3}}<br /> <br /> &lt;/pre &gt;<br /> <br /> ::Done! [[User:Kmdenmark|Kmdenmark]] ([[User talk:Kmdenmark|talk]]) 15:10, July 24, 2019 (EDT)<br /> <br /> ==Open letters ==<br /> Please add this under the Open letters heading, at the very bottom of the page:<br /> &lt;nowiki&gt;<br /> {{PagesInCategory|Open letters|mode=inline}} <br /> &lt;/nowiki &gt;<br /> (but without the 'nowiki' bits. This should then list the open letters. [[User:Kmdenmark]] [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 23:04, 2 May 2019 (EDT)<br /> :Done! [[User:Kmdenmark|Kmdenmark]] ([[User talk:Kmdenmark|talk]]) 15:56, 11 May 2019 (EDT)<br /> :: {{Thanks}} [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:55, July 22, 2019 (EDT)<br /> <br /> ==Edits done ==<br /> * Remove the comma and space before the Nutrients heading <br /> * Treatments: Add Pain relief (analgesics)<br /> [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 14:01, 5 November 2018 (EST)<br /> [[User:Kmdenmark]] can you do this? [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:09, 29 April 2019 (EDT)<br /> ::Edits done [[User:Kmdenmark|Kmdenmark]] ([[User talk:Kmdenmark|talk]]) 18:46, 2 May 2019 (EDT)<br /> :::Thanks [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 23:04, 2 May 2019 (EDT)<br /> <br /> == How should the main page be organized? ==<br /> <br /> I worry that if we add bullets to all the sections, the page will become impossibly long (I have a hard time with page scrolling...). I like the compactness of having links in paragraph form but understand it makes it hard to read. Wonder if there is a compromise? --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 05:51, 27 November 2015 (PST)<br /> <br /> : My vote would be to use wiki categories to organize everything. [[User:Analogue|Analogue]] ([[User talk:Analogue|talk]]) 00:36, 28 November 2015 (PST)<br /> <br /> :: I agree that would be good in the long run – I think for now the purpose of the main page is just to give folks a sense of which articles they can contribute to, because 99% of the content someone might search for isn't actually here yet – of course there is so much more now that the front page may be becoming a little overwhelming and should probably be pared down. Would the idea then be to link to the category pages from the main page? If we create categories, we should probably have a discussion about what are the right categories ::--[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:41, 28 November 2015 (PST)<br /> <br /> ::: Yes that's what I was thinking, front page could list/link to the categories. You've already essentially been organizing it in categories already. [[User:Analogue|Analogue]] ([[User talk:Analogue|talk]]) 15:17, 28 November 2015 (PST)<br /> <br /> Maybe we can start a discussion here about categories? Ollie and others might be more likely to see it over here: http://my.meaction.net/local_chapters/mepedia --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:43, 28 November 2015 (PST) Actually – I will start a discussion and direct folks to this talk page.<br /> <br /> With these decisions I think we should bear in mind it's less a case of &quot;Should we do X?&quot; but the question is &quot;Should we do X or Y FIRST?&quot;. In terms of priority I think covering the key content areas and filling out stub pages is more important so the wiki becomes genuinely useful as soon as possible. I like the current home page as it's easy to see what needs doing and shows what the wiki is for, but I completely agree it will ultimately change in future and categories are likely to work well as they allow us to specify where a page goes IN that page, rather than elsewhere. In the meantime I would prefer comma-separated lists rather than bullets so the page is not unnecessarily long. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 01:56, 29 November 2015 (PST)<br /> <br /> Can I suggest that if we keep the current format (at least for now) that we add commas between items so we have &quot;Item 1, Item 2, Item 3&quot; rather than &quot;Item 1 Item 2 Item 3&quot; as it will be much clearer. At the same time we can also reorder the items alphabetically. Later we could use each section as the basis for a category. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 02:25, 29 November 2015 (PST)<br /> <br /> I agree with commas or a period. Blogs: Blog 1.Blog 2.Blog 3.Blog 4 The black will stand out against the red or blue. Also, I agree while being populated keeping it the way it is with commas or periods added will work or just leave alone if no one is up to putting them in. I guess in future it would make sense that '''each heading''' that now exists becomes '''a page''' and each of these pages is listed on the '''MAIN PAGE'''.--[[User:DxCFS|DxCFS]] ([[User talk:DxCFS|talk]]) 15:39, 29 November 2015 (PST)<br /> <br /> This all sounds great! The page as it stands now isn't at all a problem for me but everyone is different in terms of their capacities and just want to make sure the current layout isn't a barrier to others participating. I do think as we build out new pages, it would be wise, though, to keep categories in mind as it will save time. I wonder if categories are mutually exclusive or if a single article can be tagged with multiple categories? --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 16:50, 30 November 2015 (PST)<br /> <br /> I've reformatted the very first section (infectious agents) so the items are in alphabetical order, and comma separated. I see this as a temporary solution - the more I think about it the more I am inclined to agree we should use categories for these things as the category is specified within the specific page, and category lists are created automatically. But at least for now the commas and ordering help readability. Let me know if you think it looks like an improvements, and I can reformat the rest. Where names are like &quot;The Lancet&quot; we can alphabetise based on the first proper word, eg Lancet. Generally I think we should alphabetise based on the page title (eg Jonathan Edwards goes under J) to keep things simple. Perhaps once we have created the vast majority of the stub pages, we can look to reformat. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 04:28, 5 December 2015 (PST)<br /> <br /> Hi Olliec,<br /> <br /> I think the comma will work even though I can barely see it it seems to at least put 2 spaces between each item and the alphabetizing will probably help a lot. Right now we see a GIANT main page and I think the main page should eventually be just the main heading without the items under them and then you access that header which is its own page. Then the items for just that header will come up which I think will lend itself to better navigation and just easier on they eyes whether items remain as they are or the category option is used.<br /> <br /> Nothing like the blue link eye burn that is much like what you get with Reddit. Plus scrolling is a pain for initial navigation for a lot of patients. But if this is not in the near future then yes, start plugging in commas and alphabetizing and I hope someone else can help you out because right now I just can't. --[[User:DxCFS|DxCFS]] ([[User talk:DxCFS|talk]]) 08:35, 7 December 2015 (PST)<br /> <br /> please can we make the capitalisation consistent for the links/pages ? it's much easier to do this now, than fix it afterwards.--[[User:Suelala|Suelala]] ([[User talk:Suelala|talk]]) 21:56, 7 December 2015 (PST)<br /> <br /> I agree we must fix the capitalization. We're already seeing broken links as there is a mismatch. I figure best to copy Wikipedia which seems to say that title capitalise the first letter ONLY, unless it's a proper name. ie we have titles like these: &quot;Cognitive behavioral therapy&quot;, &quot;Post-exertional malaise&quot;, &quot;Royal Free Hospital&quot;, &quot;Nancy Klimas&quot;. No link should start with a lower-case letter (I think it's impossible for a page to actually have a lower case start letter). I've added this to the guidelines. [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 01:08, 9 December 2015 (PST)<br /> <br /> Reading everything above it looks like adding commas into some of the topic lists in the last section will help. I am happy to go in and clean this up by doing that.<br /> <br /> == Using Categories ==<br /> <br /> Here are some examples of existing category pages (i think these are the only ones):<br /> <br /> http://www.me-pedia.org/index.php?title=Category:Diagnoses<br /> http://www.me-pedia.org/index.php?title=Category:Definitions<br /> http://www.me-pedia.org/index.php?title=Category:Medical_hypotheses<br /> <br /> Categories can also have hierarchies: https://www.mediawiki.org/wiki/Help:Categories<br /> <br /> I actually like having a listing of nearly every article *somewhere* as it helps me to monitor where we are in this early stage. So perhaps we keep what we have but put a section higher up with top level categories so folks can use that for browsing and scroll down only if they want to? --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:49, 28 November 2015 (PST)<br /> : This link shows ALL articles: http://me-pedia.org/index.php?title=Special%3AAllPages&amp;from=&amp;to=&amp;namespace=0&amp;hideredirects=1 [[User:Olliec|Olliec]] ([[User talk:Olliec|talk]]) 00:58, 10 December 2015 (PST)<br /> <br /> There are also some great category extensions: https://www.mediawiki.org/wiki/Category:Category_extensions --[[User:JenB|JenB]] ([[User talk:JenB|talk]]) 04:59, 28 November 2015 (PST)<br /> <br /> {{collapse bottom}}<br /> <br /> ==Page layout and contents ==<br /> <br /> ===Category extension code for &quot;By country&quot;===<br /> Can you remove numbers? Put bullets or nothing. Also, can we put Categories of Africa, Asia, Australia &amp; New Zealand in a line instead of stacked; one after the other. There must be a code that can line them up! I really, really hate the category extensions and even if you use them you don't have to organize the front page using them. I think it makes things messier. I really don't think I can express enough how the front page cannot have all this crap on it. Better to have a subheading, click on the subheading and you get what you want. --[[User:DxCFS|DxCFS]] ([[User talk:DxCFS|talk]]) 20:12, 24 April 2016 (PDT)<br /> <br /> === How can we make the contents more presentable? ===<br /> <br /> This Contents page is embarrassingly unsightly, at least for the general public.<br /> &lt;br&gt;Is there some way that we can make it more presentable to the general public?<br /> &lt;br&gt;(I love the use of categories, maybe there is some way to hide/show individual categories?)<br /> &lt;br&gt;[[User:Pyrrhus|Pyrrhus]] ([[User talk:Pyrrhus|talk]]) 22:40, 26 February 2019 (EST)<br /> :Portals might be the way to do this. Check the new ''List of Portals'' and ''MEpedia portals'' in progress - linked to the top and bottom of the Main page, and to each individual portal eg [[Portal:Digestive system]]. These are suggested links from the portal skeleton eg Browsebar template, I'm currently working on them based on example layout on Wikipedia, and a list of categories is part of that. An overall category page would also be helpful. [[User:Notjusttired|notjusttired]] ([[User talk:Notjusttired|talk]]) 11:15, 29 April 2019 (EDT)<br /> <br /> ===How is this page to be maintained? ===<br /> <br /> With the ongoing changes to our Categories and sub-Categories, how can we ensure that this page is up-to-date?<br /> &lt;br&gt;Do we need to categorize the remaining static links on this page?<br /> &lt;br&gt;[[User:Pyrrhus|Pyrrhus]] ([[User talk:Pyrrhus|talk]]) 18:43, 5 March 2019 (EST)</div>

Simon F https://me-pedia.org/w/index.php?title=Talk:Ongoing_research_for_cures&diff=242600 2024-02-16T15:44:49Z

<p>Simon F:Simon F moved page Talk:Ongoing research for cures to Talk:Treatment trials:Reflects the content of the page better</p> <hr /> <div>#REDIRECT [[Talk:Treatment trials]]</div>

Simon F https://me-pedia.org/w/index.php?title=Talk:Treatment_trials&diff=242599 2024-02-16T15:44:49Z

<p>Simon F:Simon F moved page Talk:Ongoing research for cures to Talk:Treatment trials:Reflects the content of the page better</p> <hr /> <div>== Improvements to the page -- [[User:Simon F|Simon F]] ([[User talk:Simon F|talk]]) 14:03, January 29, 2024 (UTC) ==<br /> <br /> The table is too wide. Any suggestions for improving it?<br /> I consider the column &quot;Test subjects&quot; to add only very little additional information to the table. I am considering deleting it.<br /> <br /> The title of the page is inaccurate and outdated.<br /> As time passes the &quot;ongoing research&quot; will be completed and results will be available. Furthermore, &quot;research for cures&quot; is too vague and inaccurate - &quot;registered clinical trials&quot; reflects better the content of the table.<br /> I suggest a new page title &quot;Registered clinical trials and results&quot; or better even &quot;List of treatment trials and results&quot;<br /> <br /> Further work planned:<br /> * List all trials that have an estimated date of completion after Jan 1st, 2022 from other sources as well (WHO list)<br /> * Complete the list with the published results<br /> * Gradually add trials that were completed before 2022<br /> * Regularly (every 1-2 weeks) update the list with new trials<br /> * Regularly (every 1-2 months) update the list with the published results</div>

Simon F https://me-pedia.org/w/index.php?title=Ongoing_research_for_cures&diff=242598 2024-02-16T15:44:49Z

<p>Simon F:Simon F moved page Ongoing research for cures to Treatment trials:Reflects the content of the page better</p> <hr /> <div>#REDIRECT [[Treatment trials]]</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242597 2024-02-16T15:44:48Z

<p>Simon F:Simon F moved page Ongoing research for cures to Treatment trials:Reflects the content of the page better</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Talk:Treatment_trials&diff=242596 2024-02-16T15:41:56Z

<p>Simon F:updated content</p> <hr /> <div>== Improvements to the page -- [[User:Simon F|Simon F]] ([[User talk:Simon F|talk]]) 14:03, January 29, 2024 (UTC) ==<br /> <br /> The table is too wide. Any suggestions for improving it?<br /> I consider the column &quot;Test subjects&quot; to add only very little additional information to the table. I am considering deleting it.<br /> <br /> The title of the page is inaccurate and outdated.<br /> As time passes the &quot;ongoing research&quot; will be completed and results will be available. Furthermore, &quot;research for cures&quot; is too vague and inaccurate - &quot;registered clinical trials&quot; reflects better the content of the table.<br /> I suggest a new page title &quot;Registered clinical trials and results&quot; or better even &quot;List of treatment trials and results&quot;<br /> <br /> Further work planned:<br /> * List all trials that have an estimated date of completion after Jan 1st, 2022 from other sources as well (WHO list)<br /> * Complete the list with the published results<br /> * Gradually add trials that were completed before 2022<br /> * Regularly (every 1-2 weeks) update the list with new trials<br /> * Regularly (every 1-2 months) update the list with the published results</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242595 2024-02-16T14:29:13Z

<p>Simon F:shortened abbreviations table</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type (TT)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects (CS)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase (TP)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category (TC)<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242594 2024-02-16T14:27:29Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242593 2024-02-16T10:10:18Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]] &amp; [[Chlorella Pyreinodosa]]<br /> |biomarkers (B12, metilmalonic acid, homocysteine)<br /> |[https://clinicaltrials.gov/study/NCT06255600 NCT06255600]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-06-11<br /> |D<br /> |[[Rapamycin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06257420 NCT06257420]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242590 2024-02-13T15:40:58Z

<p>Simon F:minor corrections and changes</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |general symptoms- [https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242589 2024-02-12T17:40:54Z

<p>Simon F:/* Completed trials */ minor corrections</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |&lt;s&gt;2022-02-21&lt;/s&gt;<br /> |&lt;s&gt;D&lt;/s&gt;<br /> |&lt;s&gt;[[Ampion]]&lt;/s&gt;<br /> |&lt;s&gt;respiratory&lt;/s&gt;<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 &lt;s&gt;NCT04880161&lt;/s&gt;]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |physical exhaustion, systemic inflammation, endothelial function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |mood+, fatigue-[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |fatigue-[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |fatigue--[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |fatigue-, sleep issues-[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |no significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |cognitive=[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |inconclusive[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242584 2024-02-12T09:58:46Z

<p>Simon F:corrections and results</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |inconclusive[https://www.liebertpub.com/doi/abs/10.1089/can.2022.0135]<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |&lt;s&gt;2022-02-21&lt;/s&gt;<br /> |&lt;s&gt;D&lt;/s&gt;<br /> |&lt;s&gt;[[Ampion]]&lt;/s&gt;<br /> |&lt;s&gt;respiratory&lt;/s&gt;<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 &lt;s&gt;NCT04880161&lt;/s&gt;]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |headache-, coughing/sneezing-, hypoxemia-, dyspnea-[https://europeanjournalofrespiratorymedicine.com/wp-content/uploads/2021/03/EJRM-121.pdf]<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |negligible improvements[https://prospekta.ru/assets/s/%D0%A0%D0%B5%D0%B7%D1%83%D0%BB%D1%8C%D1%82%D0%B0%D1%82%D1%8B%20%D0%A0%D0%9A%D0%98%20%D0%9C%D0%9C%D0%9D-%D0%9C%D0%90%D0%A0-003_%D0%A2%D0%BA%D0%B0%D1%87%D0%B5%D0%B2%D0%B0_%D0%9E_%D0%9D__%D0%9C%D1%85%D0%B8%D1%82%D0%B0%D1%80%D1%8F%D0%BD_%D0%AD_%D0%90__%D0%9A%D0%BE%D0%BB%D1%8B%D1%85%D0%B0%D0%BB%D0%BE%D0%B2_%D0%98_%D0%92.pdf]<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |fatigue-[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |Physical Exhaustion , Systemic Inflammatory State and Endothelial Function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> | -<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242579 2024-02-10T16:06:26Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |D<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |Physical Exhaustion , Systemic Inflammatory State and Endothelial Function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-15<br /> |P<br /> |[[Vimida]] (app)<br /> |fatigue, depression, anxiety, quality of life, ...<br /> |[https://clinicaltrials.gov/study/NCT06251518 NCT06251518]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Ciwujia]] granules<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06245642 NCT06245642]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242578 2024-02-10T15:55:09Z

<p>Simon F:corrections and added treatment category for ongoing trials</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |D<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |Physical Exhaustion , Systemic Inflammatory State and Endothelial Function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |O<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |O<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2024-03-27<br /> |R<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |P<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |P<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |R<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |R<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |D<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |O<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |R<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |S<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |C<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |R<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |P<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |O<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |D<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |R<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |P<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |S<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |D<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |R<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |R<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |S<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |O<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |C<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |D<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |D<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |O<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |P<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |O<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |R<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |R<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |O<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |R<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |O<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |R<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |R<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |O<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |S<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |R<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |C<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |O<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |R<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |D<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |S<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |S<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |R<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |R<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |O<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |S<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |O<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |O<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |S<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |D<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |O<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |S<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |O<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |C<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |S<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |D<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |D<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |D<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |S<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |R<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |C<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |O<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |D<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |R<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |D<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |D<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |R<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |P<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |S<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |R<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |O<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |O<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |R<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |R<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |C<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |D<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |P<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |C<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |O<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |S<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |R<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |D<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |P<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |O<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |R<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |R<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |O<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |D<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |R<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |D<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |O<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |O<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |R<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |D<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242577 2024-02-09T16:19:11Z

<p>Simon F:added legend for &quot;complementary and alternative medicine&quot;</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment category<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |C<br /> |Complementary and alternative medicine<br /> |-<br /> |D<br /> |Drug (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |D<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |Physical Exhaustion , Systemic Inflammatory State and Endothelial Function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242576 2024-02-09T16:16:43Z

<p>Simon F:added column for treatment type</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations and symbols are used in the tables below:<br /> {| class=&quot;wikitable&quot;<br /> |+Trial type<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TT'''<br /> |'''Trial type'''<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Condition of the trial subjects<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''CS'''<br /> |'''Condition of the trial Subjects'''<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |PC<br /> |Post COVID<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Trial phase<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''PH'''<br /> |'''Trial phase'''<br /> |-<br /> |1-4<br /> |Trial phase 1-4<br /> |-<br /> |n/a<br /> |Trial phase not applicable<br /> |}<br /> {| class=&quot;wikitable&quot;<br /> |+Treatment categories<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |'''TC'''<br /> |'''Treatment category'''<br /> |-<br /> |D<br /> |Drugs (pharmacotherapy)<br /> |-<br /> |O<br /> |Other<br /> |-<br /> |P<br /> |Psychotherapy<br /> |-<br /> |R<br /> |Rehabilitation<br /> |-<br /> |S<br /> |Supplements<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !TC<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''TT'''<br /> !TP<br /> !CS<br /> |-<br /> |2022-01-19<br /> |O<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |O<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |O<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |D<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |S<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |D<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |D<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |R<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |D<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |R<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |S<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |R<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |R<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |D<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |D<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |R<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |D<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |C<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |O<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |O<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |S<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |O<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |R<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |S<br /> |Bioarginina C (supplement)<br /> |Physical Exhaustion , Systemic Inflammatory State and Endothelial Function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |R<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |R<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |R<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |R<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |R<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |D<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |O<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |R<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |R<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |D<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |D<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |C<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |D<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |D<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |R<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |D<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |S<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |R<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |R<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |R<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |D<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |O<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |R<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |D<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |S<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |D<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |O<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |R<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |R<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |C<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |O<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |P<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |R<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |S<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |D<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |R<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |D<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |R<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |O<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |R<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |R<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |C<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |D<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |R<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |R<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |R<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |D<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |S<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |D<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |R<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |R<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |P<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |O<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |D<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |D<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |D<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |D<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |D<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |D<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |D<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |O<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |R<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |P<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |C<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |R<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |D<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |D<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |C<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |C<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |D<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |D<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |C<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |O<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |R<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |S<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |O<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |D<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |R<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |R<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |C<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |O<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |P<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |D<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |R<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |R<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |P<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |O<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |R<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242575 2024-02-07T14:32:31Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-10<br /> |Inspiratory muscle training<br /> |pulmonary, strength<br /> |[https://www.clinicaltrials.gov/study/NCT04811859 NCT04811859]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-03-30<br /> |[[Rehabilitation]] (online)<br /> |respiratory, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05074771 NCT05074771]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-05-01<br /> |[[Physical exercise]] (online)<br /> |pain, cardiopulmonary capacity, mood, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04983394 NCT04983394]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-06-08<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-18<br /> |Bioarginina C (supplement)<br /> |Physical Exhaustion , Systemic Inflammatory State and Endothelial Function<br /> |[https://www.clinicaltrials.gov/study/NCT04947488 NCT04947488]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-20<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-15<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-02<br /> |Diaphragmatic exercises / incentive spirometer<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05787275 NCT05787275]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |Cardiopulmonary exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05035628 NCT05035628]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-02<br /> |Cardiorespiratory [[rehabilitation]] (online)<br /> |fatigue, PEM, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05973136 NCT05973136]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |Sensory re-education training<br /> |disability, tactile sensation, handgrip strength<br /> |[https://www.clinicaltrials.gov/study/NCT05911113 NCT05911113]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-30<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |[[Vagus nerve stimulation]]<br /> |dysautonomia, fatigue, dyspnea, PEM, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05630040 NCT05630040]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-15<br /> |ImmuneRecov (proteins &amp; supplements)<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06166030 NCT06166030]<br /> |<br /> |OLT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |Multimodal integrative naturopathic therapy<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04927403 NCT04927403]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242573 2024-02-07T09:36:20Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-08<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-20<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-01<br /> |Circuit training<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05323331 NCT05323331]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-10<br /> |Diagrammatic breathing &amp; resistance training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05543551 NCT05543551]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Pulsed ectromagnetic field / pulmonary rehabilitation<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05379517 NCT05379517]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-30<br /> |[[Physiotherapy]] (online)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-02-28<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05496842 NCT05496842]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-29<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05658536 NCT05658536]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |[[Physical exercise]] / [[Incentive Spirometry|incentive spirometry]]<br /> |pulmonary, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06191367 NCT06191367]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Cognitive behavioral therapy]]<br /> |fitness, fatigue, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05196451 NCT05196451]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-07<br /> |Pulmonary rehabilitation (online) / physical activity<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05299333 NCT05299333]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Breathing techniques]] &amp; [[yoga]]<br /> |pulmonary, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05732571 NCT05732571]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[CPAP]]<br /> |fog, neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT06052514 NCT06052514]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-05-31<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05918978 NCT05918978]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877534 NCT05877534]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-15<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242567 2024-02-06T19:11:48Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-08<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-20<br /> |High tone power therapy<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05217771 NCT05217771]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |Whole body vibration training<br /> |fitness, many<br /> |[https://www.clinicaltrials.gov/study/NCT05119634 NCT05119634]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Telephysiotherapy<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |Multidisciplinary [[rehabilitation]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04961333 NCT04961333]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-01<br /> |Robotic assisted hand [[rehabilitation]]<br /> |health, independence, range of motion<br /> |[https://www.clinicaltrials.gov/study/NCT06137716 NCT06137716]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-23<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05402007 NCT05402007]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-01<br /> |Physical exercise (online)<br /> |fitness, sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05381675 NCT05381675]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-08-10<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06002230 NCT06002230]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-30<br /> |Physical exercise<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05961462 NCT05961462]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |Respiratory music therapy<br /> |pulmonary, many<br /> |[https://www.clinicaltrials.gov/study/NCT05231512 NCT05231512]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Sodium citrate]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06204432 NCT06204432]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05094622 NCT05094622]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2024-12-31<br /> |Interrupted sitting<br /> |PEM, cognitive, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453175 NCT05453175]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[Physical exercise]] (sensors + app)<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05922865 NCT05922865]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-04-28<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05852873 NCT05852873]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-15<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242539 2024-02-05T08:23:56Z

<p>Simon F:fixed date</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-08<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Telephysiotherapy<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-15<br /> |[[Loratidin]]<br /> |many<br /> |[https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjgzMzM=&amp;Enc=&amp;userName=043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242538 2024-02-05T08:19:30Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-14<br /> |Formula C™<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04828668 NCT04828668]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-08<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Telephysiotherapy<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Balneotherapy]] &amp; [[aquatic exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05765591 NCT05765591]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Cupping therapy]]<br /> |immunological<br /> |[https://www.clinicaltrials.gov/study/NCT05901337 NCT05901337]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-01<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05977166 NCT05977166]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-30<br /> |[[Physiotherapy]] with [[neuromodulation]]<br /> |fatigue, sleep, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05681455 NCT05681455]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-22<br /> |Inspiratory &amp; expiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05597774 NCT05597774]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Acupuncture]]<br /> |fog, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06144320 NCT06144320]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05841498 NCT05841498]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, sleep, pain<br /> |[https://www.clinicaltrials.gov/study/NCT05753202 NCT05753202]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-08<br /> |[[Physical exercise]] (online)<br /> |fitness, cardiopulmonary, sleep<br /> |[https://www.clinicaltrials.gov/study/NCT05205460 NCT05205460]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |Inspiratory muscle training<br /> |fitness, blood pressure, neurovascular ctrl.<br /> |[https://www.clinicaltrials.gov/study/NCT06091384 NCT06091384]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |Inspiratory muscle training<br /> |dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05024474 NCT05024474]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Cognitive rehabilitation therapy|CRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05732285 NCT05732285]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-01<br /> |[[Diet]] &amp; [[self-management]] (online)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05057676 NCT05057676]<br /> |<br /> |OLT<br /> |n/a<br /> |many<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242537 2024-02-04T15:49:02Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-08<br /> |[[Prospekta]]<br /> |asthenia<br /> |[https://www.clinicaltrials.gov/study/NCT05074888 NCT05074888]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-07-31<br /> |[[TDCS]]<br /> |fatigue, cognition, depression, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05252481 NCT05252481]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-10<br /> |[[Curcumin]] &amp; [[Boswellia serrata]] &amp; [[Vitamin C]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05150782 NCT05150782]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Telephysiotherapy<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06016192 NCT06016192]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Resistance exercise]]<br /> |fitness, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04900961 NCT04900961]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive behavioral therapy|CBT]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |pain, anxiety, depression, insomnia<br /> |[https://www.clinicaltrials.gov/study/NCT05815693 NCT05815693]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Electrical stimulation]]<br /> |pain, fatigue, strength, endurance<br /> |[https://www.clinicaltrials.gov/study/NCT05200858 NCT05200858]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-30<br /> |[[Cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05338749 NCT05338749]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-06-30<br /> |[[Physical exercise]]<br /> |cardiovascular<br /> |[https://www.clinicaltrials.gov/study/NCT06168006 NCT06168006]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[VIX001]]<br /> |cognitive, neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05947617 NCT05947617]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[IVIG]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159283 NCT06159283]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2028-09-30<br /> |[[Anti-inflammatory diets|Anti-inflammatory diet]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05977179 NCT05977179]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-03-31<br /> |Cognitive r[[Rehabilitation|ehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06086379 NCT06086379]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242535 2024-02-03T13:44:17Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-01<br /> |[[Nordic walking]]<br /> |fatigue, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT05453188 NCT05453188]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-07-30<br /> |Laser [[acupuncture]]<br /> |immunological, dyspnea<br /> |[https://www.clinicaltrials.gov/study/NCT05271500 NCT05271500]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Telephysiotherapy<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-12<br /> |[[Homeopathy]]<br /> |cough, dyspnea, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05715554 NCT05715554]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05780450 NCT05780450]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-10-31<br /> |[[Medical marijuana]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05467904 NCT05467904]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-14<br /> |Physical and respiratory [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629884 NCT05629884]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Cognitive training]]<br /> |cognitive, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05629897 NCT05629897]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Niagen]]<br /> |cognitive, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT04809974 NCT04809974]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Online respiratory [[physiotherapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05572346 NCT05572346]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Psychology]]<br /> |sleep, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05951803 NCT05951803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; physical [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05254301 NCT05254301]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Faecal microbiota transplantation]]<br /> |sleep, anxiety, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05556733 NCT05556733]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445427 NCT05445427]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-30<br /> |[[Breathing exercises]]<br /> |blood oxygen level<br /> |[https://www.clinicaltrials.gov/study/NCT06165835 NCT06165835]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-05-15<br /> |[[Stellate ganglion block]]<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT06055270 NCT06055270]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242534 2024-02-03T05:50:21Z

<p>Simon F:typo</p> <hr /> <div>This page lists the recent as well as the ongoing registered medical trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results - if available.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Telephysiotherapy<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242533 2024-02-03T05:48:49Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-21<br /> |[[Ampion]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04880161 NCT04880161]<br /> |<br /> |RCT<br /> |1<br /> |LC, PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-30<br /> |Telephysiotherapy<br /> |fitness, quality of life<br /> |[https://www.clinicaltrials.gov/study/NCT04742946 NCT04742946]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-02<br /> |Portable oxygen concentrator<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05212831 NCT05212831]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829] <br /> [https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-06<br /> |[[Osteopathy]] &amp; [[Physiotherapy]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05012826 NCT05012826]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-06<br /> |[[Triphala]] &amp; [[HIIT]]<br /> |immune system, oxidative stress<br /> |[https://www.clinicaltrials.gov/study/NCT06208761 NCT06208761]<br /> |non-conclusive results[https://www.clinicaltrials.gov/study/NCT06208761]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-30<br /> |[[Omega 3 fatty acid|Omega 3]] &amp; Telerehabilitation<br /> |fatigue, fitness, depression, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT06063031 NCT06063031]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Ketogenic diet|Low carb diet]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05836402 NCT05836402]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |External encounter counterpulsation<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05668039 NCT05668039]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-15<br /> |Umbilical cord mesenchymal [[stem cell therapy]]<br /> |caugh<br /> |[https://www.clinicaltrials.gov/study/NCT05808400 NCT05808400]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |Mild [[hyperthermia]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06204458 NCT06204458]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |Complementary &amp; Integrative medicine online<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06004362 NCT06004362]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2028-09-30<br /> |Weight loss<br /> |fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05880108 NCT05880108]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242522 2024-02-02T19:14:57Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-03-15<br /> |[[Palmitoylethanolamide]] &amp; [[Luteolin]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05311852 NCT05311852]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829][https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05566483 NCT05566483]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Physical exercise]]<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT06065033 NCT06065033]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Cardiopulmonary exercise test|Cardiopulmonary exercise]]<br /> |cardiopulmonary <br /> |[https://www.clinicaltrials.gov/study/NCT05539950 NCT05539950]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242521 2024-02-02T18:03:29Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-20<br /> |[[Physical exercise]] &amp; oxygen<br /> |cardiopulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04898205 NCT04898205]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-04-22<br /> |[[Homeopathy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05104749 NCT05104749]<br /> |<br /> |RCT<br /> |3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-04<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05080244 NCT05080244]<br /> |<br /> |RCT<br /> |n/a<br /> |COVID<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[Vagus nerve stimulation]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05205577 NCT05205577]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-06-30<br /> |Adhera (fatigue digital program)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05483829 NCT05483829][https://www.clinicaltrials.gov/study/NCT05631171 NCT05631171]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-10-14<br /> |Cardiorespiratory telerehabilitation<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04996212 NCT04996212]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-28<br /> |[[Tai chi]]<br /> |strength<br /> |[https://www.clinicaltrials.gov/study/NCT05501067 NCT05501067]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-27<br /> |[[Rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05855356 NCT05855356]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Bright light therapy|Bright light]]<br /> |fatigue, insomnia, anxiety, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05677932 NCT05677932]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |Home-based [[physical exercise]]<br /> |strength, fatigue, dyspnoea<br /> |[https://www.clinicaltrials.gov/study/NCT06073002 NCT06073002]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-19<br /> |[[Acupuncture]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05212688 NCT05212688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |Physical and cognitive exercising<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05218174 NCT05218174]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242520 2024-02-02T16:12:56Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-31<br /> |[[Stellate ganglion block]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05812209 NCT05812209]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-30<br /> |[[Resveratrol]] &amp; [[Quercetin]]<br /> |asthma, breathing<br /> |[https://www.clinicaltrials.gov/study/NCT05601180 NCT05601180]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[Acupuncture]] &amp; [[Traditional Chinese medicine|TCM]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06042777 NCT06042777]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-08-31<br /> |[[Cetirizine]] / [[Famotidine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05946551 NCT05946551]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-01<br /> |[[Physical exercise]]<br /> |fatigue, fitness<br /> |[https://www.clinicaltrials.gov/study/NCT06142240 NCT06142240]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242519 2024-02-02T15:15:12Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Physiotherapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05040893 NCT05040893]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-01-31<br /> |Sub-symptom threshold [[Aerobic exercise|Aerobic rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06172803 NCT06172803]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-30<br /> |[[Psychology]] &amp; [[breathing exercises]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05705154 NCT05705154]<br /> |<br /> |RCT<br /> |1/2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-11-01<br /> |[[Testofen]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05795816 NCT05795816]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-01<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911906 NCT05911906]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[Stem cell therapy]]<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT06156241 NCT06156241]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-08-01<br /> |[[Incentive Spirometry|Incentive spirometr]]&lt;nowiki/&gt;er respiratory training<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT06231225 NCT06231225]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242517 2024-02-01T15:30:47Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-04-30<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05840237 NCT05840237]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-01<br /> |Pulmonary [[rehabilitation]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT05244044 NCT05244044]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |Multi-disciplinary recovery program <br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05167227 NCT05167227]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-01-31<br /> |Smell training and trigeminal nerve stimulation<br /> |parosmia<br /> |[https://www.clinicaltrials.gov/study/NCT05855369 NCT05855369]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242516 2024-02-01T14:11:26Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-28<br /> |[[Computerized cognitive training]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05571852 NCT05571852]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-09-01<br /> |[[Self-management]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05268523 NCT05268523]<br /> |<br /> |RCT<br /> |1/2<br /> |LC, PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-05-31<br /> |[[Physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05204511 NCT05204511]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-11-30<br /> |[[Telerehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05817032 NCT05817032]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Yoga]] &amp; breathing &amp; [[meditation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05139979 NCT05139979]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Tai chi|TaiChi-DTx]] (software)<br /> |cognitive, physical activity<br /> |[https://www.clinicaltrials.gov/study/NCT05419219 NCT05419219]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-02-29<br /> |Cognitive [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05731570 NCT05731570]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-09-30<br /> |Electronic case management (software)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05019963 NCT05019963]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |NeuroFlex (brain training software)<br /> |cognitive, fatigue, depression<br /> |[https://www.clinicaltrials.gov/study/NCT05705193 NCT05705193]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Acupuncture|Electro-acupuncture]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890508 NCT05890508]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=User:Simon_F&diff=242515 2024-02-01T13:38:32Z

<p>Simon F:deleted content</p> <hr /> <div></div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242512 2024-02-01T09:10:07Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-04-21<br /> |[[Omega 3 fatty acid|Omega 3]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05121766 NCT05121766]<br /> |<br /> |RCT<br /> |1<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Beclomethasone]]<br /> |hyposmia<br /> |[https://www.clinicaltrials.gov/study/NCT05970731 NCT05970731]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |Virtual home-based [[rehabilitation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05298878 NCT05298878]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |Improvement of symptoms[https://journals.sagepub.com/doi/full/10.1177/27536351241227261]<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Psychoeducation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05167266 NCT05167266]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-06-30<br /> |[[Self-management]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06208696 NCT06208696]<br /> |<br /> |NRCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-08-31<br /> |[[CPPC]]<br /> |cognitive, psychological<br /> |[https://clinicaltrials.gov/study/NCT06223971 NCT06223971]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[Nitrate]]<br /> |physical fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05618574 NCT05618574]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-09-30<br /> |Balance acceptance and commitment<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT06231238 NCT06231238]<br /> |<br /> |RCT<br /> |2<br /> |LC, PC<br /> |-<br /> |2025-12-01<br /> |[[Amantadine]]<br /> |cognitive, fatigue, anxiety, depression<br /> |[https://clinicaltrials.gov/study/NCT06234462 NCT06234462]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242511 2024-01-31T20:20:59Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Completed trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Estimated study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-30<br /> |[[:Category:Diets|Diet]] &amp; [[fasting]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06214455 NCT06214455]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Talk:Treatment_trials&diff=242510 2024-01-31T14:42:14Z

<p>Simon F:updated to reflect new page layout</p> <hr /> <div>== Improvements to the page -- [[User:Simon F|Simon F]] ([[User talk:Simon F|talk]]) 14:03, January 29, 2024 (UTC) ==<br /> <br /> The table is too wide. Any suggestions for improving it?<br /> I consider the column &quot;Test subjects&quot; to add only very little additional information to the table. I am considering deleting it.<br /> <br /> The title of the page is inaccurate and outdated.<br /> As time passes the &quot;ongoing research&quot; will be completed and results will be available. Furthermore, &quot;research for cures&quot; is too vague and inaccurate - &quot;registered clinical trials&quot; reflects better the content of the table.<br /> I suggest a new page title &quot;Registered clinical trials and results&quot;<br /> <br /> Further work planned:<br /> * List all trials that were completed after Jan 1st, 2022<br /> * Complete the list with the published results<br /> * Gradually add trials that were completed before 2022<br /> * Regularly (every 1-2 weeks) update the list with new trials<br /> * Regularly (every 1-2 months) update the list with the published results<br /> <br /> Splitting up the long tables into shorter ones:<br /> * Completed trials with negative or no published results<br /> * Completed trials with positive published results<br /> * Ongoing trials</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242509 2024-01-31T14:24:54Z

<p>Simon F:Reorganized the whole page</p> <hr /> <div>This page lists the recent as well as the ongoing registered medial trials on treatments for the symptoms of [[myalgic encephalomyelitis]] (ME) and [[Post-Acute Sequelae of COVID-19|post-acute sequelae of SARS-CoV-2 infection]] (PASC) as well as their results.<br /> <br /> == Abbreviations ==<br /> The following abbreviations are used in the table:<br /> {| class=&quot;wikitable&quot;<br /> !Abbreviation<br /> !Meaning<br /> |-<br /> |ME<br /> |Myalgic encephalomyelitis<br /> |-<br /> |LC<br /> |Long COVID<br /> |-<br /> |PC<br /> |Post COVID<br /> |-<br /> |RCT<br /> |Randomized controlled trial<br /> |-<br /> |NRCT<br /> |Non-randomized controlled trial<br /> |-<br /> |OLT<br /> |Open-label trial<br /> |}<br /> <br /> == Past studies ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-04<br /> |[[Vagus nerve stimulation]]<br /> |<br /> |[https://www.clinicaltrials.gov/study/NCT05679505 NCT05679505]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |}<br /> <br /> == Ongoing trials ==<br /> {| class=&quot;wikitable sortable&quot;<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Talk:Treatment_trials&diff=242506 2024-01-30T16:28:13Z

<p>Simon F:added section for splitting up the table</p> <hr /> <div>== Improvements to the page -- [[User:Simon F|Simon F]] ([[User talk:Simon F|talk]]) 14:03, January 29, 2024 (UTC) ==<br /> <br /> The table is too wide. Any suggestions for improving it?<br /> I moved the two columns &quot;Test subjects&quot; and &quot;Treatment status&quot; to the right of the table, because I consider these two columns to add only very little additional information to the table. I am considering deleting these two columns.<br /> <br /> The title of the page is inaccurate and outdated.<br /> As time passes the &quot;ongoing research&quot; will be completed and results will be available. Furthermore, &quot;research for cures&quot; is too vague and inaccurate - &quot;registered clinical trials&quot; reflects better the content of the table.<br /> I suggest a new page title &quot;Registered clinical trials and results&quot;<br /> <br /> Further work planned:<br /> * List all trials that were completed after Jan 1st, 2022<br /> * Complete the list with the published results<br /> * Gradually add trials that were completed before 2022<br /> * Regularly (every 1-2 weeks) update the list with new trials<br /> * Regularly (every 1-2 months) update the list with the published results<br /> <br /> Splitting up the long table into 3:<br /> * Past studies with no published results<br /> * Past studies with published results (potentially this one can be split into &quot;positive&quot; and &quot;negative&quot; results)<br /> * Ongoing studies</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242505 2024-01-30T16:24:45Z

<p>Simon F:added many new list items</p> <hr /> <div>This page lists the ongoing research on [[Myalgic encephalomyelitis]], [[Long COVID]] and [[Post COVID]]. It has not been proven that the three conditions share the same underlying mechanism, however, since the symptoms of all these conditions are very similar, there is reason to believe that research findings for one condition may be applicable for the other conditions as well.<br /> <br /> The following abbreviations are used in the table:<br /> <br /> * ME: Myalgic encephalomyelitis<br /> * LC: Long COVID<br /> * PC: Post COVID<br /> * RCT: Randomized controlled trial<br /> ** NRCT: Non-randomized controlled trial<br /> * OLT: Open-label trial<br /> <br /> {| class=&quot;wikitable sortable&quot;<br /> |+<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-01<br /> |[[Magnesium]] &amp; [[Vitamin D]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05630339 NCT05630339]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2022-10-13<br /> |Virtual self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05107440 NCT05107440]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT04836351 NCT04836351]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[Heart rate variability]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05228665 NCT05228665]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-08-31<br /> |[[Anakinra]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT05926505 NCT05926505]<br /> |<br /> |RCT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Rehabilitation]] &amp; exercise<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156176 NCT06156176]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2025-12-31<br /> |[[Ensitrelvir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06161688 NCT06161688]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[Lp299v]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05227170 NCT05227170]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F https://me-pedia.org/w/index.php?title=Treatment_trials&diff=242504 2024-01-30T15:15:15Z

<p>Simon F:Added list items</p> <hr /> <div>This page lists the ongoing research on [[Myalgic encephalomyelitis]], [[Long COVID]] and [[Post COVID]]. It has not been proven that the three conditions share the same underlying mechanism, however, since the symptoms of all these conditions are very similar, there is reason to believe that research findings for one condition may be applicable for the other conditions as well.<br /> <br /> The following abbreviations are used in the table:<br /> <br /> * ME: Myalgic encephalomyelitis<br /> * LC: Long COVID<br /> * PC: Post COVID<br /> * RCT: Randomized controlled trial<br /> ** NRCT: Non-randomized controlled trial<br /> * OLT: Open-label trial<br /> <br /> {| class=&quot;wikitable sortable&quot;<br /> |+<br /> !'''Study completion'''<br /> !'''Treatment'''<br /> !Targeted symptoms<br /> !'''Link / study ID'''<br /> !Study results<br /> !'''Trial type'''<br /> !'''Trial phase'''<br /> !Trial subjects<br /> |-<br /> |2022-01-19<br /> |[[Biosound]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05848401 NCT05848401]<br /> | -<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2022-01-21<br /> |[[Virtual SFCAMINA]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04593225 NCT04593225]<br /> | -<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-01-31<br /> |[[Ruconest]]<br /> |neurological<br /> |[https://clinicaltrials.gov/study/NCT04705831 NCT04705831]<br /> | -<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-01-31<br /> |[[S-1226]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04949386 NCT04949386]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-02-22<br /> |[[Fluvoxamine]] ([[SSRI]])<br /> |parosmia<br /> |[https://clinicaltrials.gov/study/NCT05216614 NCT05216614]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-03-07<br /> |[[Sodium pyruvate]] nasal spray<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04871815 NCT04871815]<br /> |<br /> |OLT<br /> |2/3<br /> |LC, PC<br /> |-<br /> |2022-06-29<br /> |[[AXA1125]]<br /> |muscles, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05152849 NCT05152849]<br /> |Improvement in fatigue[https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00123-2/fulltext]<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2022-07-18<br /> |[[LYT-100]]<br /> |respiratory<br /> |[https://clinicaltrials.gov/study/NCT04652518 NCT04652518]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2022-11-30<br /> |Computerized cognitive training<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05582603 NCT05582603]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2022-12-05<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05608629 NCT05608629]<br /> |Improvement in mood and fatigue for some participants[https://www.clinicaltrials.gov/study/NCT05608629?tab=results]<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2022-12-20<br /> |[[Emoxypine]] &amp; [[Meldonium]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05939622 NCT05939622]<br /> |Improvement in fatigue[https://www.sciencedirect.com/science/article/pii/S0753332223015214]<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2022-12-31<br /> |[[Oxaloacetate]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05273372 NCT05273372]<br /> |Significant reduction of fatigue[https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03488-3]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-06<br /> |[[Medical marijuana]] (CBD)<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04997395 NCT04997395]<br /> | -<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2023-01-23<br /> |[[Low dose naltrexone]] &amp; [[NAD+]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04604704 NCT04604704]<br /> | -<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-01-31<br /> |[[Quercetin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05730660 NCT05730660]<br /> |Improvement in fatigue and sleep[https://www.sciencedirect.com/science/article/pii/S0753332223012519]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |[[ImmunoVita]] ([[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04301609 NCT04301609]<br /> |No significant improvements[https://www.mdpi.com/2072-6643/15/21/4504]<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2023-01-31<br /> |Inspiratory muscle training<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05196529 NCT05196529]<br /> | -<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2023-02-22<br /> |[[Vortioxetine]] ([[SSRI]])<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05047952 NCT05047952]<br /> |No cognitive improvement[https://academic.oup.com/brain/advance-article-abstract/doi/10.1093/brain/awad377/7344681]<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-03-30<br /> |[[Vagus nerve stimulation]]<br /> |neuropsychological<br /> |[https://www.clinicaltrials.gov/study/NCT05389592 NCT05389592]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-03-31<br /> |[[RSLV-132]]<br /> |fatigue<br /> |[https://clinicaltrials.gov/study/NCT04944121 NCT04944121]<br /> | -<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-05-18<br /> |[[Dextroamphetamine]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05597722 NCT05597722]<br /> |<br /> |RCT<br /> |4<br /> |PC<br /> |-<br /> |2023-05-23<br /> |[[Hydrogen water]] &amp; [[biofeedback]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05397626 NCT05397626]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2023-06-06<br /> |[[Plasma Exchange Therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05445674 NCT05445674]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-06-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05566379 NCT05566379]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-07-21<br /> |[[Lithium]]<br /> |fatigue, fog<br /> |[https://www.clinicaltrials.gov/study/NCT05618587 NCT05618587]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-07-27<br /> |[[TNX-102 SL]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05472090 NCT05472090]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-07-31<br /> |[[Valacyclovir]] &amp; [[Celecoxib]] (IMC-2)<br /> |fatigue, pain, POTS<br /> |[https://ir.virios.com/news/press-releases/detail/100/virios-therapeutics-announcespositive-data-demonstrating Virios press release]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2023-08-11<br /> |[[PRS-220]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT05473533 NCT05473533]<br /> |<br /> |RCT<br /> |1<br /> | n/a<br /> |-<br /> |2023-08-31<br /> |[[Rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05599906 NCT05599906]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-08-31<br /> |[[Montelukast]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04695704 NCT04695704]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2023-09-12<br /> |[[Metoprolol]] ([[beta blocker]])<br /> |tachycardias, POTS, hypertension<br /> |[https://www.clinicaltrials.gov/study/NCT05096884 NCT05096884]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2023-09-12<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05576662 NCT05576662]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-09-30<br /> |Physical exercise<br /> |physical &amp; mental fitness<br /> |[https://www.clinicaltrials.gov/study/NCT05848518 NCT05848518]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2023-09-30<br /> |[[Active coping]]<br /> |pain<br /> |[https://www.clinicaltrials.gov/study/NCT05894629 NCT05894629]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[GET]] &amp; [[Cognitive behavioral therapy|CBT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05534997 NCT05534997]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-10-01<br /> |[[Meplazumab]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813587 NCT05813587]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-04<br /> |[[Somatropin]] (growth hormone)<br /> |hormonal<br /> |[https://clinicaltrials.gov/study/NCT03554265 NCT03554265]<br /> |<br /> |NRCT<br /> |3<br /> |PC<br /> |-<br /> |2023-10-18<br /> |[[Zofin]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05228899 NCT05228899]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-10-30<br /> |[[Vericiguat]]<br /> |fatigue, PEM<br /> |[https://clinicaltrials.gov/study/NCT05697640 NCT05697640]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-11-01<br /> |IV [[Rintatolimod]] (Ampligen)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05592418 NCT05592418]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2023-11-03<br /> |[[Probiotic]]: VSL#3®<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874089 NCT05874089]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-01<br /> |[[Pimozide]]<br /> |tinitus<br /> |[https://clinicaltrials.gov/study/NCT05507372 NCT05507372]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-11<br /> |[[Probiotic]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05975034 NCT05975034]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-30<br /> |[[Fampridine]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05274477 NCT05274477]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-30<br /> |[[Stellate ganglion block]] <br /> &amp; [[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638620 NCT05638620]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2023-12-30<br /> |[[Yoga]] &amp; self-management<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05697042 NCT05697042]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Probiotic|Pre-probiotic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06013072 NCT06013072]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Remdesivir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04978259 NCT04978259]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[CI-581a]], [[CI-581b]] ([[glutamate modulator]])<br /> |depression<br /> |[https://www.clinicaltrials.gov/study/NCT05690503 NCT05690503]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2023-12-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |pulmonary<br /> |[https://www.clinicaltrials.gov/study/NCT04905888 NCT04905888]<br /> |<br /> |open RCT<br /> |2<br /> |LC<br /> |-<br /> |2023-12-31<br /> |[[Creatine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT02374112 NCT02374112]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-01-31<br /> |[[Bupivacaine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05664711 NCT05664711]<br /> |<br /> |OLT<br /> |1<br /> |ME<br /> |-<br /> |2024-02-01<br /> |[[Traditional Chinese medicine|Chinese herbal medicine]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05684952 NCT05684952]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-02-01<br /> |[[Autologous stem-cell transplantation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05669261 NCT05669261]<br /> |<br /> |OLT<br /> |1<br /> |LC, PC<br /> |-<br /> |2024-02-01<br /> |[[Solriamfetol]]<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04622293 NCT04622293]<br /> |<br /> |RCT<br /> |4<br /> |ME<br /> |-<br /> |2024-02-29<br /> |Home-based physical training<br /> |fitness, fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05360563 NCT05360563]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-03-31<br /> |[[Nirmatrelvir]] &amp; [[Ritonavir]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05823896 NCT05823896]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-03-31<br /> |[[Nutrition]] &amp; [[chronobiology]] &amp; [[Exercise|physical exercise]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05719493 NCT05719493]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-03-31<br /> |[[BIO 300]]<br /> |respiratory<br /> |[https://www.clinicaltrials.gov/study/NCT04482595 NCT04482595]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-06<br /> |[[IVIG]] (immunotherapy)<br /> |neurological<br /> |[https://www.clinicaltrials.gov/study/NCT05350774 NCT05350774]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-04-20<br /> |Inspiratory muscle training<br /> |health parameters, fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06091358 NCT06091358]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-05-31<br /> |[[Hydroxy gas]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159296 NCT06159296]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-01<br /> |[[Low dose naltrexone]] (oral)<br /> |pain, inflammation, fatigue<br /> |[https://clinicaltrials.gov/study/NCT05430152 NCT05430152]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-01<br /> |[[Sirolimus]]<br /> |pulmonary fibrosis<br /> |[https://www.clinicaltrials.gov/study/NCT04948203 NCT04948203]<br /> |<br /> |OLT<br /> |3<br /> |COVID<br /> |-<br /> |2024-06-15<br /> |[[Amygdala and Insula Retraining Program|Amygdala &amp; insula retraining]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05851846 NCT05851846]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-06-28<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06074848 NCT06074848]<br /> |<br /> |OLT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Vitamin K|Vitamin K2]] &amp; [[Vitamin D|D3]]<br /> |biomarkers<br /> |[https://www.clinicaltrials.gov/study/NCT05356936 NCT05356936]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-06-30<br /> |[[Temelimab]]<br /> |neuropsychiatric<br /> |[https://www.clinicaltrials.gov/study/NCT05497089 NCT05497089]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT04842448 NCT04842448]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-06-30<br /> |[[LAU-7b]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05999435 NCT05999435]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2024-07-01<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05595369 NCT05595369]<br /> |<br /> |RCT<br /> |2<br /> |COVID, LC<br /> |-<br /> |2024-07-30<br /> |[[Qigong exercise|Qigong]]<br /> |physical health<br /> |[https://www.clinicaltrials.gov/study/NCT05675995 NCT05675995]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-07-30<br /> |[[Lithium]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06108297 NCT06108297]<br /> |<br /> |OLT<br /> |1<br /> |LC<br /> |-<br /> |2024-07-31<br /> |[[Incentive Spirometry|Incentive spirometry]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05813873 NCT05813873]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-08-01<br /> |[[GWAS]] (Genome-wide association study)<br /> |many<br /> |[https://www.decodeme.org.uk/our-gwas-data-analysis-plan/ DecodeME]<br /> |<br /> |GWAS<br /> |n/a<br /> |ME<br /> |-<br /> |2024-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06159309 NCT06159309]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-01<br /> |[[Ivabradin]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05481177 NCT05481177]<br /> |<br /> |RCT<br /> |4<br /> |LC, PC<br /> |-<br /> |2024-09-25<br /> |[[Ultrasound]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06189066 NCT06189066]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-09-30<br /> |[[Psychotherapy|Psychotherapeutic]] intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05453201 NCT05453201]<br /> |<br /> |OLT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-10-31<br /> |[[Nirmatrelvir]] &amp; ​[[Ritonavir]] ([[Paxlovid]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05668091 NCT05668091]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-10-31<br /> |[[RegeneCyte]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05682560 NCT05682560]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-11-30<br /> |[[Efgartigimod]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05633407 NCT05633407]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-11-30<br /> |[[Hydrogen water]]<br /> |fatigue, physical function, stress<br /> |[https://www.clinicaltrials.gov/study/NCT06227273 NCT06227273]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-01<br /> |[[Cognitive rehabilitation]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT0567604 NCT0567604]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-01<br /> |[[Sauna]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05931497 NCT05931497]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Mindfulness and meditation|Mindfulness]] with Muse S™ Headband<br /> |stress, anxiety<br /> |[https://www.clinicaltrials.gov/study/NCT05199233 NCT05199233]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]] &amp; [[Vitamin B1]], [[Vitamin B6|B6]] and [[Vitamin B12|B12]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05638633 NCT05638633]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Photobiomodulation]]<br /> |oral complaints<br /> |[https://www.clinicaltrials.gov/study/NCT05760092 NCT05760092]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Cognitive trainig]] &amp; [[physical activity]] &amp; [[Mindfulness and meditation|mindfulness]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05846126 NCT05846126]<br /> |<br /> |RCT<br /> |n/a<br /> |LC, PC<br /> |-<br /> |2024-12-31<br /> |[[Metformin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06147050 NCT06147050]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2024-12-31<br /> |[[Atorvastatin]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT04904536 NCT04904536]<br /> |<br /> |OLT<br /> |3<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Prednisolone]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05986422 NCT05986422]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2024-12-31<br /> |Cacao [[flavonoid]]<br /> |fatigue, handgrip strength, perceived wellbeing<br /> |[https://www.clinicaltrials.gov/study/NCT06064838 NCT06064838]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2024-12-31<br /> |[[Melatonin]] &amp; [[Zinc]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05454683 NCT05454683]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2024-12-31<br /> |[[Floradapt Intensive GI]] ([[Probiotic]])<br /> |GI inflammation, many<br /> |[https://www.clinicaltrials.gov/study/NCT06211062 NCT06211062]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-01-15<br /> |[[Chiropractic]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT05693064 NCT05693064]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-01-30<br /> |[[Immunoadsorption|Repeat immunoadsorption]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05629988 NCT05629988]<br /> |<br /> |OLT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-01-31<br /> |[[Nicotinamide riboside]] &amp; [[MBRT]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05703074 NCT05703074]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-01-31<br /> |[[TDCS]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05791812 NCT05791812]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-02-28<br /> |[[Immunoadsorption]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05710770 NCT05710770]<br /> |<br /> |RCT<br /> |2<br /> |PC, ME<br /> |-<br /> |2025-02-28<br /> |[[DAOIB]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05764538 NCT05764538]<br /> |<br /> |OLT<br /> |2<br /> |LC<br /> |-<br /> |2025-03-01<br /> |[[Vagus nerve stimulation]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05918965 NCT05918965]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-03-31<br /> |[[Immulina TM|Immulina TM (]][[:Category:Supplements|supplement]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05524532 NCT05524532]<br /> |<br /> |RCT<br /> |n/a<br /> |PC, ME<br /> |-<br /> |2025-03-31<br /> |[[Apollo wearable]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06097442 NCT06097442]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[Mindfulness and meditation|Mindfulness]]<br /> |mental health<br /> |[https://www.clinicaltrials.gov/study/NCT05676008 NCT05676008]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-04-30<br /> |[[N-acetylcysteine]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT0454216 NCT0454216]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2025-05-15<br /> |[[Amantadine]]<br /> |cognitive, mood<br /> |[https://www.clinicaltrials.gov/study/NCT06055244 NCT06055244]<br /> |<br /> |OLT<br /> |1<br /> |PC<br /> |-<br /> |2025-05-15<br /> |Fluvoxamine<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05874037 NCT05874037]<br /> |<br /> |RCT<br /> |2/3<br /> |LC<br /> |-<br /> |2025-05-18<br /> |[[Fluvoxamine]] &amp; [[Metformin]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06128967 NCT06128967]<br /> |<br /> |RCT<br /> |3<br /> |LC<br /> |-<br /> |2025-05-31<br /> |[[BC007]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05911009 NCT05911009]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-06-01<br /> |[[Pycnogenol]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05890534 NCT05890534]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2025-07-31<br /> |[[AER002]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05877508 NCT05877508]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2025-08-31<br /> |[[Vagus nerve stimulation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06170645 NCT06170645]<br /> |<br /> |RCT<br /> |n/a<br /> |ME<br /> |-<br /> |2025-08-31<br /> |[[Hyperbaric oxygen therapy]]<br /> |neurocognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06118138 NCT06118138]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-20<br /> |[[Mesenchymal stromal cell therapy|HB-adMSCs]] (allogeneic)<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05126563 NCT05126563]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |2025-12-30<br /> |[[Hyperbaric oxygen therapy]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06082518 NCT06082518]<br /> |<br /> |OLT<br /> |n/a<br /> |PC<br /> |-<br /> |2025-12-31<br /> |Water-based activity<br /> |fatigue, cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT06142253 NCT06142253]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Imatinib]] / [[Infliximab]]<br /> |many<br /> |[https://clinicaltrials.gov/study/NCT05220280 NCT05220280]<br /> |<br /> |OLT<br /> |4<br /> |LC<br /> |-<br /> |2025-12-31<br /> |[[Ibudilast]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05513560 NCT05513560]<br /> |<br /> |RCT<br /> |3<br /> |PC<br /> |-<br /> |2026-06-01<br /> |Breath control technique<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05851859 NCT05851859]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-01-31<br /> |Mind body intervention<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06045338 NCT06045338]<br /> |<br /> |OLT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-02-28<br /> |[[TCM]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT06095258 NCT06095258]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-03-01<br /> |[[Medium chain fatty acid|MCTs]] &amp; [[Safflower oil]]<br /> |fog<br /> |[https://www.clinicaltrials.gov/study/NCT05705648 NCT05705648]<br /> |<br /> |RCT<br /> |n/a<br /> |PC<br /> |-<br /> |2026-03-30<br /> |Comprehensive [[rehabilitation]]<br /> |fatigue<br /> |[https://www.clinicaltrials.gov/study/NCT06156202 NCT06156202]<br /> |<br /> |RCT<br /> |n/a<br /> |LC<br /> |-<br /> |2026-03-31<br /> |[[AT1001]] ([[Larazotide]])<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05747534 NCT05747534]<br /> |<br /> |RCT<br /> |2<br /> |LC<br /> |-<br /> |2026-04-01<br /> |[[Lightning Process]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05236465 NCT05236465]<br /> |<br /> |OLT<br /> |n/a<br /> |ME<br /> |-<br /> |2026-12-31<br /> |[[Low dose naltrexone]]<br /> |POTS<br /> |[https://www.clinicaltrials.gov/study/NCT05363514 NCT05363514]<br /> |<br /> |RCT<br /> |4<br /> | n/a<br /> |-<br /> |2028-03-01<br /> |[[Pregabalin]]<br /> |many<br /> |[https://www.clinicaltrials.gov/study/NCT05967052 NCT05967052]<br /> |<br /> |RCT<br /> |2<br /> |ME<br /> |-<br /> |2029-12-30<br /> |[[Baricitinib]]<br /> |cognitive<br /> |[https://www.clinicaltrials.gov/study/NCT05858515 NCT05858515]<br /> |<br /> |RCT<br /> |2<br /> |PC<br /> |-<br /> |unknown<br /> |[[Loratidin]]<br /> |many<br /> |[https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/es/ictrp-CTRI202207043679 CTRI/ 2022/07/043679]<br /> |<br /> |RCT<br /> |4<br /> |LC<br /> |}</div>

Simon F